Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.
A malignant kidney tumor, caused by the uncontrolled multiplication of renal stem (blastemal), stromal (STROMAL CELLS), and epithelial (EPITHELIAL CELLS) elements. However, not all three are present in every case. Several genes or chromosomal areas have been associated with Wilms tumor which is usually found in childhood as a firm lump in a child's side or ABDOMEN.
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.
A cell line derived from cultured tumor cells.
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
The total amount (cell number, weight, size or volume) of tumor cells or tissue in the body.
Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS.
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms.
A usually small, slow-growing neoplasm composed of islands of rounded, oxyphilic, or spindle-shaped cells of medium size, with moderately small vesicular nuclei, and covered by intact mucosa with a yellow cut surface. The tumor can occur anywhere in the gastrointestinal tract (and in the lungs and other sites); approximately 90% arise in the appendix. It is now established that these tumors are of neuroendocrine origin and derive from a primitive stem cell. (From Stedman, 25th ed & Holland et al., Cancer Medicine, 3d ed, p1182)
Tumors whose cells possess secretory granules and originate from the neuroectoderm, i.e., the cells of the ectoblast or epiblast that program the neuroendocrine system. Common properties across most neuroendocrine tumors include ectopic hormone production (often via APUD CELLS), the presence of tumor-associated antigens, and isozyme composition.
All tumors in the GASTROINTESTINAL TRACT arising from mesenchymal cells (MESODERM) except those of smooth muscle cells (LEIOMYOMA) or Schwann cells (SCHWANNOMA).
Genes that inhibit expression of the tumorigenic phenotype. They are normally involved in holding cellular growth in check. When tumor suppressor genes are inactivated or lost, a barrier to normal proliferation is removed and unregulated growth is possible.
Nuclear phosphoprotein encoded by the p53 gene (GENES, P53) whose normal function is to control CELL PROLIFERATION and APOPTOSIS. A mutant or absent p53 protein has been found in LEUKEMIA; OSTEOSARCOMA; LUNG CANCER; and COLORECTAL CANCER.
Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)
Tumors or cancers of the KIDNEY.
Experimentally induced mammary neoplasms in animals to provide a model for studying human BREAST NEOPLASMS.
Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
A pathologic process consisting of the proliferation of blood vessels in abnormal tissues or in abnormal positions.
The milieu surrounding neoplasms consisting of cells, vessels, soluble factors, and molecules, that can influence and be influenced by, the neoplasm's growth.
Proteins that are normally involved in holding cellular growth in check. Deficiencies or abnormalities in these proteins may lead to unregulated cell growth and tumor development.
A malignant epithelial tumor with a glandular organization.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
Tumors or cancer located in bone tissue or specific BONES.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Transplantation between animals of different species.
Tumors or cancer of the human BREAST.
Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.
In vivo methods of screening investigative anticancer drugs, biologic response modifiers or radiotherapies. Human tumor tissue or cells are transplanted into mice or rats followed by tumor treatment regimens. A variety of outcomes are monitored to assess antitumor effectiveness.
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
Tumors or cancer of the LUNG.
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
All of the processes involved in increasing CELL NUMBER including CELL DIVISION.
Tumors or cancer of the GASTROINTESTINAL TRACT, from the MOUTH to the ANAL CANAL.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
Neoplasms of the brain and spinal cord derived from glial cells which vary from histologically benign forms to highly anaplastic and malignant tumors. Fibrillary astrocytomas are the most common type and may be classified in order of increasing malignancy (grades I through IV). In the first two decades of life, astrocytomas tend to originate in the cerebellar hemispheres; in adults, they most frequently arise in the cerebrum and frequently undergo malignant transformation. (From Devita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2013-7; Holland et al., Cancer Medicine, 3d ed, p1082)
Tumors or cancer of the LIVER.
Elements of limited time intervals, contributing to particular results or situations.
Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)
Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses.
Tumors or cancer of the COLON.
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
A variation of the PCR technique in which cDNA is made from RNA via reverse transcription. The resultant cDNA is then amplified using standard PCR protocols.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
DNA present in neoplastic tissue.
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.
Experimental transplantation of neoplasms in laboratory animals for research purposes.
Tumors or cancer of the SKIN.
A sarcoma derived from deep fibrous tissue, characterized by bundles of immature proliferating fibroblasts with variable collagen formation, which tends to invade locally and metastasize by the bloodstream. (Stedman, 25th ed)
Mice homozygous for the mutant autosomal recessive gene "scid" which is located on the centromeric end of chromosome 16. These mice lack mature, functional lymphocytes and are thus highly susceptible to lethal opportunistic infections if not chronically treated with antibiotics. The lack of B- and T-cell immunity resembles severe combined immunodeficiency (SCID) syndrome in human infants. SCID mice are useful as animal models since they are receptive to implantation of a human immune system producing SCID-human (SCID-hu) hematochimeric mice.
The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION.
Tomography using x-ray transmission and a computer algorithm to reconstruct the image.
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.
Neoplasms composed of primordial GERM CELLS of embryonic GONADS or of elements of the germ layers of the EMBRYO, MAMMALIAN. The concept does not refer to neoplasms located in the gonads or present in an embryo or FETUS.
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.
The relationship between the dose of an administered drug and the response of the organism to the drug.
Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms.
A peripheral blood picture resembling that of leukemia or indistinguishable from it on the basis of morphologic appearance alone. (Dorland, 27th ed)
The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.
A malignant neoplasm of the germinal tissue of the GONADS; MEDIASTINUM; or pineal region. Germinomas are uniform in appearance, consisting of large, round cells with vesicular nuclei and clear or finely granular eosinophilic-staining cytoplasm. (Stedman, 265th ed; from DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, pp1642-3)
Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.
Antibodies produced by a single clone of cells.
Experimentally induced neoplasms of CONNECTIVE TISSUE in animals to provide a model for studying human SARCOMA.
A relatively common neoplasm of the CENTRAL NERVOUS SYSTEM that arises from arachnoidal cells. The majority are well differentiated vascular tumors which grow slowly and have a low potential to be invasive, although malignant subtypes occur. Meningiomas have a predilection to arise from the parasagittal region, cerebral convexity, sphenoidal ridge, olfactory groove, and SPINAL CANAL. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2056-7)
A transplantable, poorly differentiated malignant tumor which appeared originally as a spontaneous breast carcinoma in a mouse. It grows in both solid and ascitic forms.
Experimentally induced tumor that produces MELANIN in animals to provide a model for studying human MELANOMA.
A malignant tumor of the bone which always arises in the medullary tissue, occurring more often in cylindrical bones. The tumor occurs usually before the age of 20, about twice as frequently in males as in females.
The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway.
Compounds that are used in medicine as sources of radiation for radiotherapy and for diagnostic purposes. They have numerous uses in research and industry. (Martindale, The Extra Pharmacopoeia, 30th ed, p1161)
Non-invasive method of demonstrating internal anatomy based on the principle that atomic nuclei in a strong magnetic field absorb pulses of radiofrequency energy and emit them as radiowaves which can be reconstructed into computerized images. The concept includes proton spin tomographic techniques.
Tumors or cancer of the MAMMARY GLAND in animals (MAMMARY GLANDS, ANIMAL).
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.
Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)
The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability.
An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.
A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)
Established cell cultures that have the potential to propagate indefinitely.
Agents and endogenous substances that antagonize or inhibit the development of new blood vessels.
A rare but highly lethal childhood tumor found almost exclusively in infants. Histopathologically, it resembles RHABDOMYOSARCOMA but the tumor cells are not of myogenic origin. Although it arises primarily in the kidney, it may be found in other parts of the body. The rhabdoid cytomorphology is believed to be the expression of a very primitive malignant cell. (From Holland et al., Cancer Medicine, 3d ed, p2210)
The determination of the pattern of genes expressed at the level of GENETIC TRANSCRIPTION, under specific circumstances or in a specific cell.
A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin. The neoplasms may be histologically the same or different, and may be found in the same or different sites.
A cytologic technique for measuring the functional capacity of tumor stem cells by assaying their activity. It is used primarily for the in vitro testing of antineoplastic agents.
Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens.
Identification of proteins or peptides that have been electrophoretically separated by blot transferring from the electrophoresis gel to strips of nitrocellulose paper, followed by labeling with antibody probes.
The uptake of naked or purified DNA by CELLS, usually meaning the process as it occurs in eukaryotic cells. It is analogous to bacterial transformation (TRANSFORMATION, BACTERIAL) and both are routinely employed in GENE TRANSFER TECHNIQUES.
A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.
Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.
Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.
A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)
Exfoliate neoplastic cells circulating in the blood and associated with metastasizing tumors.
The movement of cells from one location to another. Distinguish from CYTOKINESIS which is the process of dividing the CYTOPLASM of a cell.
A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.
A neoplasm composed entirely of GRANULOSA CELLS, occurring mostly in the OVARY. In the adult form, it may contain some THECA CELLS. This tumor often produces ESTRADIOL and INHIBIN. The excess estrogen exposure can lead to other malignancies in women and PRECOCIOUS PUBERTY in girls. In rare cases, granulosa cell tumors have been identified in the TESTES.
An imaging technique using compounds labelled with short-lived positron-emitting radionuclides (such as carbon-11, nitrogen-13, oxygen-15 and fluorine-18) to measure cell metabolism. It has been useful in study of soft tissues such as CANCER; CARDIOVASCULAR SYSTEM; and brain. SINGLE-PHOTON EMISSION-COMPUTED TOMOGRAPHY is closely related to positron emission tomography, but uses isotopes with longer half-lives and resolution is lower.
The highest dose of a biologically active agent given during a chronic study that will not reduce longevity from effects other than carcinogenicity. (from Lewis Dictionary of Toxicology, 1st ed)
A general term for various neoplastic diseases of the lymphoid tissue.
In vitro method for producing large amounts of specific DNA or RNA fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). The essential steps include thermal denaturation of the double-stranded target molecules, annealing of the primers to their complementary sequences, and extension of the annealed primers by enzymatic synthesis with DNA polymerase. The reaction is efficient, specific, and extremely sensitive. Uses for the reaction include disease diagnosis, detection of difficult-to-isolate pathogens, mutation analysis, genetic testing, DNA sequencing, and analyzing evolutionary relationships.
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.
Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN.
Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection.
A condition of decreased oxygen content at the cellular level.
The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.
A malignant solid tumor arising from mesenchymal tissues which normally differentiate to form striated muscle. It can occur in a wide variety of sites. It is divided into four distinct types: pleomorphic, predominantly in male adults; alveolar (RHABDOMYOSARCOMA, ALVEOLAR), mainly in adolescents and young adults; embryonal (RHABDOMYOSARCOMA, EMBRYONAL), predominantly in infants and children; and botryoidal, also in young children. It is one of the most frequently occurring soft tissue sarcomas and the most common in children under 15. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p2186; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, pp1647-9)
Tumor suppressor genes located on the short arm of human chromosome 17 and coding for the phosphoprotein p53.
Accumulation of a drug or chemical substance in various organs (including those not relevant to its pharmacologic or therapeutic action). This distribution depends on the blood flow or perfusion rate of the organ, the ability of the drug to penetrate organ membranes, tissue specificity, protein binding. The distribution is usually expressed as tissue to plasma ratios.
One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.
The statistical reproducibility of measurements (often in a clinical context), including the testing of instrumentation or techniques to obtain reproducible results. The concept includes reproducibility of physiological measurements, which may be used to develop rules to assess probability or prognosis, or response to a stimulus; reproducibility of occurrence of a condition; and reproducibility of experimental results.
A type of connective tissue neoplasm typically arising from intralobular stroma of the breast. It is characterized by the rapid enlargement of an asymmetric firm mobile mass. Histologically, its leaf-like stromal clefts are lined by EPITHELIAL CELLS. Rare phyllodes tumor of the prostate is also known.
The loss of one allele at a specific locus, caused by a deletion mutation; or loss of a chromosome from a chromosome pair, resulting in abnormal HEMIZYGOSITY. It is detected when heterozygous markers for a locus appear monomorphic because one of the ALLELES was deleted.
A carcinoma discovered by Dr. Margaret R. Lewis of the Wistar Institute in 1951. This tumor originated spontaneously as a carcinoma of the lung of a C57BL mouse. The tumor does not appear to be grossly hemorrhagic and the majority of the tumor tissue is a semifirm homogeneous mass. (From Cancer Chemother Rep 2 1972 Nov;(3)1:325) It is also called 3LL and LLC and is used as a transplantable malignancy.
Tumors or cancer of the STOMACH.
Highly proliferative, self-renewing, and colony-forming stem cells which give rise to NEOPLASMS.
RNA present in neoplastic tissue.
Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.
The phenotypic manifestation of a gene or genes by the processes of GENETIC TRANSCRIPTION and GENETIC TRANSLATION.
They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system.
Addition of methyl groups to DNA. DNA methyltransferases (DNA methylases) perform this reaction using S-ADENOSYLMETHIONINE as the methyl group donor.
Tumors or cancer of the URINARY BLADDER.
A group of malignant tumors of the nervous system that feature primitive cells with elements of neuronal and/or glial differentiation. Use of this term is limited by some authors to central nervous system tumors and others include neoplasms of similar origin which arise extracranially (i.e., NEUROECTODERMAL TUMORS, PRIMITIVE, PERIPHERAL). This term is also occasionally used as a synonym for MEDULLOBLASTOMA. In general, these tumors arise in the first decade of life and tend to be highly malignant. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, p2059)
Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.
A tumor necrosis factor receptor subtype that has specificity for TUMOR NECROSIS FACTOR ALPHA and LYMPHOTOXIN ALPHA. It is constitutively expressed in most tissues and is a key mediator of tumor necrosis factor signaling in the vast majority of cells. The activated receptor signals via a conserved death domain that associates with specific TNF RECEPTOR-ASSOCIATED FACTORS in the CYTOPLASM.
A protein-tyrosine kinase receptor that is specific for STEM CELL FACTOR. This interaction is crucial for the development of hematopoietic, gonadal, and pigment stem cells. Genetic mutations that disrupt the expression of PROTO-ONCOGENE PROTEINS C-KIT are associated with PIEBALDISM, while overexpression or constitutive activation of the c-kit protein-tyrosine kinase is associated with tumorigenesis.
A CELL CYCLE and tumor growth marker which can be readily detected using IMMUNOCYTOCHEMISTRY methods. Ki-67 is a nuclear antigen present only in the nuclei of cycling cells.
Vaccines or candidate vaccines designed to prevent or treat cancer. Vaccines are produced using the patient's own whole tumor cells as the source of antigens, or using tumor-specific antigens, often recombinantly produced.
Experimentally induced tumors of the LIVER.
A bone tumor composed of cellular spindle-cell stroma containing scattered multinucleated giant cells resembling osteoclasts. The tumors range from benign to frankly malignant lesions. The tumor occurs most frequently in an end of a long tubular bone in young adults. (From Dorland, 27th ed; Stedman, 25th ed)
A negative regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins.
Techniques and strategies which include the use of coding sequences and other conventional or radical means to transform or modify cells for the purpose of treating or reversing disease conditions.
In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test.
Family of retrovirus-associated DNA sequences (ras) originally isolated from Harvey (H-ras, Ha-ras, rasH) and Kirsten (K-ras, Ki-ras, rasK) murine sarcoma viruses. Ras genes are widely conserved among animal species and sequences corresponding to both H-ras and K-ras genes have been detected in human, avian, murine, and non-vertebrate genomes. The closely related N-ras gene has been detected in human neuroblastoma and sarcoma cell lines. All genes of the family have a similar exon-intron structure and each encodes a p21 protein.
A benign epithelial tumor with a glandular organization.
A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
Hybridization of a nucleic acid sample to a very large set of OLIGONUCLEOTIDE PROBES, which have been attached individually in columns and rows to a solid support, to determine a BASE SEQUENCE, or to detect variations in a gene sequence, GENE EXPRESSION, or for GENE MAPPING.
An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed.
DNA sequences which are recognized (directly or indirectly) and bound by a DNA-dependent RNA polymerase during the initiation of transcription. Highly conserved sequences within the promoter include the Pribnow box in bacteria and the TATA BOX in eukaryotes.
Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.
Lymphocytes that show specificity for autologous tumor cells. Ex vivo isolation and culturing of TIL with interleukin-2, followed by reinfusion into the patient, is one form of adoptive immunotherapy of cancer.
A blue-red, extremely painful vascular neoplasm involving a glomeriform arteriovenous anastomosis (glomus body), which may be found anywhere in the skin, most often in the distal portion of the fingers and toes, especially beneath the nail. It is composed of specialized pericytes (sometimes termed glomus cells), usually in single encapsulated nodular masses which may be several millimeters in diameter (From Stedman, 27th ed). CHEMODECTOMA, a tumor of NEURAL CREST origin, is also sometimes called a glomus tumor.
A positive regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins.
Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity.
Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment.
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.
Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.
The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment.
Gonadal interstitial or stromal cell neoplasm composed of only LEYDIG CELLS. These tumors may produce one or more of the steroid hormones such as ANDROGENS; ESTROGENS; and CORTICOSTEROIDS. Clinical symptoms include testicular swelling, GYNECOMASTIA, sexual precocity in children, or virilization (VIRILISM) in females.
Small double-stranded, non-protein coding RNAs (21-31 nucleotides) involved in GENE SILENCING functions, especially RNA INTERFERENCE (RNAi). Endogenously, siRNAs are generated from dsRNAs (RNA, DOUBLE-STRANDED) by the same ribonuclease, Dicer, that generates miRNAs (MICRORNAS). The perfect match of the siRNAs' antisense strand to their target RNAs mediates RNAi by siRNA-guided RNA cleavage. siRNAs fall into different classes including trans-acting siRNA (tasiRNA), repeat-associated RNA (rasiRNA), small-scan RNA (scnRNA), and Piwi protein-interacting RNA (piRNA) and have different specific gene silencing functions.
Tumors of bone tissue or synovial or other soft tissue characterized by the presence of giant cells. The most common are giant cell tumor of tendon sheath and GIANT CELL TUMOR OF BONE.
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
Systems for the delivery of drugs to target sites of pharmacological actions. Technologies employed include those concerning drug preparation, route of administration, site targeting, metabolism, and toxicity.
The compound is given by intravenous injection to do POSITRON-EMISSION TOMOGRAPHY for the assessment of cerebral and myocardial glucose metabolism in various physiological or pathological states including stroke and myocardial ischemia. It is also employed for the detection of malignant tumors including those of the brain, liver, and thyroid gland. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1162)
A nonparametric method of compiling LIFE TABLES or survival tables. It combines calculated probabilities of survival and estimates to allow for observations occurring beyond a measurement threshold, which are assumed to occur randomly. Time intervals are defined as ending each time an event occurs and are therefore unequal. (From Last, A Dictionary of Epidemiology, 1995)
Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included.
A malignant neoplasm that may be classified either as a glioma or as a primitive neuroectodermal tumor of childhood (see NEUROECTODERMAL TUMOR, PRIMITIVE). The tumor occurs most frequently in the first decade of life with the most typical location being the cerebellar vermis. Histologic features include a high degree of cellularity, frequent mitotic figures, and a tendency for the cells to organize into sheets or form rosettes. Medulloblastoma have a high propensity to spread throughout the craniospinal intradural axis. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2060-1)
Malignant neoplasms arising in the neuroectoderm, the portion of the ectoderm of the early embryo that gives rise to the central and peripheral nervous systems, including some glial cells.
Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important.
An organoplatinum compound that possesses antineoplastic activity.
Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity.
The complex series of phenomena, occurring between the end of one CELL DIVISION and the end of the next, by which cellular material is duplicated and then divided between two daughter cells. The cell cycle includes INTERPHASE, which includes G0 PHASE; G1 PHASE; S PHASE; and G2 PHASE, and CELL DIVISION PHASE.
A type of IN SITU HYBRIDIZATION in which target sequences are stained with fluorescent dye so their location and size can be determined using fluorescence microscopy. This staining is sufficiently distinct that the hybridization signal can be seen both in metaphase spreads and in interphase nuclei.
Proteins which bind to DNA. The family includes proteins which bind to both double- and single-stranded DNA and also includes specific DNA binding proteins in serum which can be used as markers for malignant diseases.
Benign and malignant neoplastic processes that arise from or secondarily involve the meningeal coverings of the brain and spinal cord.
The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement.
A selective increase in the number of copies of a gene coding for a specific protein without a proportional increase in other genes. It occurs naturally via the excision of a copy of the repeating sequence from the chromosome and its extrachromosomal replication in a plasmid, or via the production of an RNA transcript of the entire repeating sequence of ribosomal RNA followed by the reverse transcription of the molecule to produce an additional copy of the original DNA sequence. Laboratory techniques have been introduced for inducing disproportional replication by unequal crossing over, uptake of DNA from lysed cells, or generation of extrachromosomal sequences from rolling circle replication.
A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2. It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors.
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
Studies which start with the identification of persons with a disease of interest and a control (comparison, referent) group without the disease. The relationship of an attribute to the disease is examined by comparing diseased and non-diseased persons with regard to the frequency or levels of the attribute in each group.
Neoplasms produced from tooth-forming tissues.
Endogenous substances, usually proteins, which are effective in the initiation, stimulation, or termination of the genetic transcription process.
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.
Infections produced by oncogenic viruses. The infections caused by DNA viruses are less numerous but more diverse than those caused by the RNA oncogenic viruses.
The action of a drug in promoting or enhancing the effectiveness of another drug.
Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body.
Tumors or cancer of the INTESTINES.
A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized form leading to cell death.
An unusual and aggressive tumor of germ-cell origin that reproduces the extraembryonic structures of the early embryo. It is the most common malignant germ cell tumor found in children. It is characterized by a labyrinthine glandular pattern of flat epithelial cells and rounded papillary processes with a central capillary (Schiller-Duval body). The tumor is rarely bilateral. Before the use of combination chemotherapy, the tumor was almost invariably fatal. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1189)
Interruption or suppression of the expression of a gene at transcriptional or translational levels.
Genes at loci that are involved in the development of WILMS TUMOR. Included are human WT1 at 11p13 and human WT2 (MTACR1) at 11p15.
The pathological process occurring in cells that are dying from irreparable injuries. It is caused by the progressive, uncontrolled action of degradative ENZYMES, leading to MITOCHONDRIAL SWELLING, nuclear flocculation, and cell lysis. It is distinct it from APOPTOSIS, which is a normal, regulated cellular process.
Agents that inhibit PROTEIN KINASES.
A glycoprotein that is secreted into the luminal surface of the epithelia in the gastrointestinal tract. It is found in the feces and pancreaticobiliary secretions and is used to monitor the response to colon cancer treatment.
Proteins prepared by recombinant DNA technology.
Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms.
Diseases of the domestic dog (Canis familiaris). This term does not include diseases of wild dogs, WOLVES; FOXES; and other Canidae for which the heading CARNIVORA is used.
The dispersed tumors are called metastatic tumors, while the original is called the primary tumor. Almost all cancers can ... Surgery is the primary method of treatment for most isolated, solid cancers and may play a role in palliation and prolongation ... "Five Things Physicians and Patients Should Question" (PDF). Choosing Wisely: An Initiative of the ABIM Foundation. Archived ... All tumor cells show the six hallmarks of cancer. These characteristics are required to produce a malignant tumor. They include ...
Such levels are common in human solid tumors, a phenomenon known as tumor hypoxia. Evofosfamide is being evaluated in clinical ... in Patients with Advanced Solid Malignancies". Clinical Cancer Research. 17 (9): 2997-3004. doi:10.1158/1078-0432.CCR-10-3425. ... Evofosfamide clinical trials (as of 21 November 2014) sorted by (Estimated) Primary Completion Date: Both, evofosfamide and ... "Follow-Up Data From a Phase 1/2 Clinical Trial of TH-302 in Solid Tumors - Press release from 12 October 2010". Archived from ...
"Study of CEP-9722 as Single-Agent Therapy and as Combination Therapy With Temozolomide in Patients With Advanced Solid Tumors ... Some cancer cells that lack the tumor suppressor PTEN may be sensitive to PARP inhibitors because of downregulation of Rad51, a ... Niraparib: In March 2017 approved by US FDA for epithelial ovarian, fallopian tube, and primary peritoneal cancer. Inhibitor of ... Started Phase III: Talazoparib after trials for advanced hematological malignancies and for advanced or recurrent solid tumors ...
The dispersed tumors are called metastatic tumors, while the original is called the primary tumor. Almost all cancers can ... Surgery is the primary method of treatment for most isolated, solid cancers and may play a role in palliation and prolongation ... Western conceptions of patients' rights for people with cancer include a duty to fully disclose the medical situation to the ... The dispersed tumors are called metastatic tumors, while the original is called the primary tumor. Almost all cancers can ...
Next, safety and tolerability were investigated in a Phase I trial involving 30 volunteers with advanced solid tumors or ... with the primary adverse event reported being gastrointestinal reaction. A Phase II study in 18 patients with pancreatic cancer ... In vivo trials demonstrated a 50-70% reduction in tumor burden for xenografted pancreatic and prostate cancers; however, ... is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with ...
The same applies to patients with melanoma and the other solid tumor cancers. Before the micrometastases colonize at a distant ... This concept pertains to melanoma, breast cancer, and other solid tumors, including colorectal, gastroesophageal, lung, head ... These cells have successfully left the primary tumor microenvironment and the SNLs, and are able to survive in a non-native ... Tumor cells found in the bone marrow are known as disseminated tumor cells (DTCs), and those found in the peripheral blood are ...
However, US is not the primary modality for the evaluation of solid tumors in the kidney, and CT is the first choice modality. ... Solid tumor in the renal sinus seen as a hypoechoic mass, later found to be lymphoma. The '1' and '2' on the US image are ... In the adult patient, a curved array transducer with center frequencies of 3-6 MHz is used, while the pediatric patient should ... Benign tumors are difficult to separate from malignant tumors using US. Thus, solid renal masses found on US are difficult to ...
... though the two main categories of tumor were classified as either cerebral lymphomas or solid tumors, such as pontine gliomas, ... Subsequent findings revealed CNH can also occur in conscious patients. Patients with tumor-induced CNH remain conscious because ... The primary difference between juvenile and adult cases of CNH is the structural identity of the tumors leading to CNH symptoms ... Most patients are seen to enter this state two to three months after the onset of CNH. Lange et al. cited a patient that ...
For example, in solid tumors such as germ cell tumors, SALL4 protein expression has become a standard diagnostic biomarker. ... Zhang L, Yan Y, Jiang Y, Cui Y, Zou Y, Qian J, Luo C, Lu Y, Wu X (Jan 2015). "The expression of SALL4 in patients with gliomas ... In many of these cancers, SALL4 expression was compared in tumor cells to the normal tissue counterpart, e.g. it is expressed ... These suggest the primary cancer-maintaining property of SALL4 is mediated through its transcriptional repressing function. ...
All solid tumors where the 5T4 tumor antigen is present. Clinical development is ongoing in renal cell carcinoma, colorectal ... sunitinib to combat advanced or metastatic renal cell carcinoma to 700 patients, with the primary endpoint being the rate of ... TroVax uses a tumor-associated antigen, 5T4, with a pox virus vector. 5T4 is found in a wide range of solid cancers and its ... TroVax is a proprietary tumor-associated antigen, 5T4, delivered by the pox virus vector, modified vaccinia virus Ankara (MVA ...
... and primary peritoneal cancer. Lutathera is an option used to treat patients with neuroendocrine tumors. Lutathera can help ... The three-story facility houses outpatient space for evaluation and treatment of solid tumor neoplasms including: lung, head ... Markey patients' have a five-year survival rate in ovarian, lung, brain, prostate, and Stage IV colorectal cancer higher than ... Each option is provided to patients by a team of experts in the innovative new treatment. CAR T-cell therapy is offered to ...
By contrast, analysis of solid tumors necessitates invasive procedures that might limit patient compliance. The ability to ... Circulating tumor cells (CTCs) are cells that have shed into the vasculature or lymphatics[1] from a primary tumor and are ... "Assessment of circulating tumor cells (CTCs) in prostate cancer patients with low-volume tumors". Pathol. Int. 60 (10): 667-72 ... "Molecular detection of micrometastases and circulating tumor cells in solid tumors". Clin. Cancer Res. 5 (8): 1950-60. PMID ...
In November 2010 the FDA approved Xgeva for the prevention of complications of bone metastases in patients with solid tumors. ... cinacalcet for primary and secondary hyperparathyroidism, a mineral metabolism complication common in patients with kidney ... an immunostimulator used to prevent infections in patients undergoing cancer chemotherapy and Enbrel, a tumor necrosis factor ... spinal cord compression or surgery to bone in adults with bone metastases from solid tumors) Kepivance (palifermin for oral ...
Tumor response rate was the primary endpoint using Response Evaluation Criteria In Solid Tumors (RECIST) criteria, , while time ... Patient with hepatic metastatic disease from neuroendocrine tumors, gastrointestinal stromal tumors other sarcomas, ocular ... The anti-tumor effects are solely based on tumor ischemia and infarction of tumor tissue, as no chemotherapeutic agents are ... It can be thought of as a type of tumor lysis syndrome. After abrupt ischemic tumor cell death, the tumor cells lyse and ...
... common unrecognised primary tumor sites are melanomas, sarcomas or testicular cancer). Benign tumors in the lung include ... or in patients with known primary cancer.[7] Solid nodules[7] ,6 mm (,100mm3). 6-8mm (100-250mm3). ,8mm (,250mm3) ... Part solid No routine follow-up. CT after 6-12 months: *If unchanged and solid component remains ,6mm: Annual CT for 5 years. ... Conversely, 10 to 20% of patients with lung cancer are diagnosed in this way.[3] If the patient has a history of smoking or the ...
MRI/CT to look for solid tumors, and tests for serum LDH and other tumor markers.[3] ... Eosinophilia can be idiopathic (primary) or, more commonly, secondary to another disease.[2][3] In the Western World, allergic ... However, immune suppression, the mechanism of action of corticosteroids, can be fatal in patients with parasitosis.[2] ... Of solid tumor neoplasms, ovarian cancer is most likely to provoke eosinophilia, though any other cancer can cause the ...
"Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment - Full Text View - ... In addition, tumor size decreased in 45% of patients. The results prove MM-151's ability to combat resistance of other EGRF ... The primary goals of the trial were to verify the safety of MM-151 and determine the dose of MM-151 alone and in combination ... A Phase 1 clinical trial for the treatment of solid tumors with MM-151 began in January 2012. This non-randomized, open-labeled ...
MRI/CT to look for solid tumors, and tests for serum LDH and other tumor markers. Based on their causes, hypereosinophilias can ... In primary cutaneous T cell lymphoma, blood and dermal eosinophilia are often seen. Lymphoma cells have also been shown to ... Patients displaying eosinophilia overexpress a gene encoding an eosinophil hematopoietin. A translocation between chromosomes 5 ... Of solid tumor neoplasms, ovarian cancer is most likely to provoke eosinophilia, though any other cancer can cause the ...
The tumors may be very small to very large, and may be solid or cystic. Histologically, the tumor consists of nests of the ... As primary ovarian mucinous tumors are usually unilateral (in one ovary), the presentation of bilateral mucinous tumors ... and the 5-year survival rate for patients with tumors confined to the ovary is approximately 75%. Clear cell tumors are ... the tumor becomes more solid. Prognosis again is dependent on the spread of the tumor, as well as how differentiated the tumor ...
The conventional Response Evaluation Criteria in Solid Tumors (RECIST) may underrepresent the merits of immunotherapies. ... The trial was conducted across 17 countries, and in July 2017, AstraZeneca announced that it had failed to meet its primary ... Mechanism of Pathway: CTLA-4 Inhibition[permanent dead link] Antoni Ribas (28 June 2012). "Tumor immunotherapy directed at PD-1 ... "Pfizer Announces Discontinuation of Phase III Clinical Trial for Patients with Advanced Melanoma". 1 April 2008. ...
Metastasis' look histologically identical to the primary tumour and are benign in nature. The peripheral subtype composes 2% of ... Men and women are equally affected, though women average four years younger than men when tumors first occur, and tumors run ... Conventional ameloblastomas have both cystic and solid neoplastic structures. Solid areas contain fibrous tissue islands or ... Present in younger patients in their second and third decades of life, often in relation to unerupted third molar. ...
Survival rates in primary brain tumors depend on the type of tumor, age, functional status of the patient, the extent of ... Given the location of primary solid neoplasms of the brain in most cases a "do-nothing" option is usually not presented. ... Tumors can be benign or malignant, can occur in different parts of the brain, and may be primary or secondary. A primary tumor ... malignant or cancerous tumors and benign tumors.[2] Cancerous tumors can be divided into primary tumors, which start within the ...
Tumor ablation of thoracic malignancies should be considered a viable treatment option for patients with early stage, primary ... It is generally used for the treatment and/or palliation of solid tumors in patients who are nonsurgical candidate. For ... For nonsurgical patients, local thermal ablation techniques have enabled local control of tumors without resection. In ... The oscillation of polar molecules produces frictional heating, ultimately generating tissue necrosis within solid tumors. ...
For Stage II patients with observable metastasis, cytoreductive surgery may be performed to debulk the volume of the tumor, ... Histologically, these tumors are characterized by mixed solid and cystic components. The mixed solid components are ... II patients will be found with the development of secondary malignant growths at lymph nodes with a distance from a primary ... With a recurrence up to 15-25% for early-stage patients, adjuvant chemotherapy needs to couple with surgical resection of tumor ...
Involvement of lymph nodes is uncommon and generally due to the tumors' spread from their primary sites. About 70% of ENLTL ... The prognosis of patients with advanced stage PBL, which is a common presentation of the disease in patients with HIV/AIDS, is ... eBL commonly presents with a jaw mass; periorbital swelling due to an orbital tumor; or an abdominal mass caused by a tumor in ... PEL occurs primarily in individuals who are immunodeficient due to HIV/AIDS infection or solid organ transplantation. EBV is ...
Only patients with measurable disease at baseline should be included in protocols where objective tumor response is the primary ... Response evaluation criteria in solid tumors (RECIST) is a set of published rules that define when tumors in cancer patients ... The criteria are specifically not meant to determine whether patients have improved or not, as these are tumor-centric, not ... Today, the majority of clinical trials evaluating cancer treatments for objective response in solid tumors use RECIST. These ...
... in Patients With Advanced Solid Tumors. Joachim Drevs, Patrizia Siegert, Michael Medinger, Klaus Mross, Ralph Strecker, Ute ... on Primary Tumor, Metastasis, Vessel Density, and Blood Flow in a Murine Renal Cell Carcinoma Model. Joachim Drevs, Inga ... and was present during the making of a new group of medications for the treatment of tumor patients called Molecular Targeted ... Affects the Anatomy of the Tumor Vascular Bed and the Functional Vascular Properties as Detected by Dynamic Enhanced Magnetic ...
This is achieved using immunohistochemistry with a cytokeratin panel to distinguish such cases from phyllodes tumors, primary ... If the tumor has metastasized, more severe symptoms will be presented, depending on the site of metastasis. Mammography is a ... In most MCB cases, patients are women over the age of 50, indicating that age is a major factor in determining the risk of ... Sonography is also often used to help diagnose MCB, where solid and cystic components may be observed. This is related to ...
... study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors. ... A multi-center phase 2 trial involving patients with Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cancer ... Previously, a European Phase I study in combination with cisplatin showed substantial evidence for anti-tumor activity. In that ... The drug has undergone a number of clinical trials, mostly for late-stage tumors as well as ovarian and prostate cancers, ...
... solid tumor masses not accompanied by effusions. The extracavitary tumors may develop in lymph nodes, bone, bone marrow, the ... "Human Herpesvirus 8-Unrelated Primary Effusion Lymphoma-Like Lymphoma in an Elderly Korean Patient with a Good Response to ... Staudt MR, Kanan Y, Jeong JH, Papin JF, Hines-Boykin R, Dittmer DP (July 2004). "The tumor microenvironment controls primary ... or to be manifested by solid tumors that were not associated with effusions, i.e. cases of extracavitary PEL. List of ...
Time to Tumor Progression for Patients [ Time Frame: Up to 6 years ]. For patients enrolled on the Phase II portion of the ... Capecitabine, Carboplatin and Weekly Paclitaxel for Patients With Solid Tumors and Adenocarcinoma of Unknown Primary. This ... Tumors Unknown Primary Tumors Adenocarcinoma Drug: Capecitabine Drug: Carboplatin Drug: Paclitaxel Phase 1 Phase 2 ... Biomodulation of capecitabine by paclitaxel and carboplatin in advanced solid tumors and adenocarcinoma of unknown primary. ...
... in Children With Relapsed/Refractory Solid Tumors, Primary CNS Tumors, and Anaplastic Large Cell Lymphoma. ... Tumor tissue (from patients with neuroblastoma) and bone marrow and/or peripheral blood (from patients with anaplastic large ... for patients with solid tumors. * At least 14 days since prior cytotoxic therapy for patients with ALCL who relapse while ... Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma. This study is ...
Brain and Central Nervous System Tumors Unspecified Childhood Solid Tumor, Protocol Specific Drug: irinotecan hydrochloride ... Primary Purpose:. Treatment. Official Title:. A Phase I Study of Temozolomide, Oral Irinotecan, and Vincristine for Children ... Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors. The safety and scientific ... Fertile patients must use effective contraception. *Neurologic deficits in patients with CNS tumors must be stable for ≥ 1 week ...
recurrent ovarian germ cell tumor. stage IV ovarian germ cell tumor. adult central nervous system germ cell tumor. ovarian ... Primary Purpose:. Treatment. Official Title:. A Phase I Dose Escalation Study of a 2 Day Oral Lapatinib Chemosensitization ... Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors. The safety and scientific validity of this study is ... Nonseminomatous Germ Cell Tumor Embryonal Carcinoma Ovarian Germ Cell Tumor Extragonadal Germ Cell Tumor ...
Prexasertib in Treating Patients with Advanced Solid Tumors Exhibiting Replicative Stress or Homologous Recombination Repair ... PRIMARY OBJECTIVE:. I. To evaluate the activity of the CHK1 inhibitor prexasertib in patients with tumors exhibiting either ... Participants must have a pathologically confirmed advanced solid tumor for which standard therapy proven to provide clinical ... Prexasertib in Treating Patients with Advanced Solid Tumors Exhibiting Replicative Stress or Homologous Recombination Repair ...
Iodine I 131 Monoclonal Antibody 8H9 in Treating Patients with Desmoplastic Small Round Cell Tumors and Other Solid Tumors ... For tumors other than DSRCT, patients must have a history of tumor progression or recurrence or failure to achieve complete ... PRIMARY OBJECTIVES: I. Define the toxicity and maximal tolerated dose (MTD) of iodine I 131 monoclonal antibody 8H9 (131I-8H9) ... Iodine I 131 Monoclonal Antibody 8H9 in Treating Patients with Desmoplastic Small Round Cell Tumors and Other Solid Tumors ...
Metastatic Malignant Solid Neoplasm , Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors ... Recombinant interleukin-12 may kill tumor cells by blocking blood flow to the tumor and by stimulating white blood cells to ... PRIMARY OBJECTIVES: I. Establish the maximum tolerated dose (MTD) and the recommended phase II dose (RP2D) of recombinant human ... Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors Brief description of study. This phase I ...
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, ... Adult - Solid Tumor Germ Cell Tumor Relapse - Refractory. *Solid Tumors - All Other ... Primary Objectives: *To utilize clinical and biological data to screen for eligibility to phase 2 pathway-targeting specific ... Adult - Solid Tumor Neurofibromatosis Sarcoma MPNST Relapse - Refractory. *Solid Tumor Neurofibromatosis Sarcoma MPNST Relapse ...
... encompassing advanced solid tumors and relapsed or refractory T-ALL/LBL). Phase 1a Secondary Objectives 1. To evaluate the ... Primary Objectives 1. To determine the maximum tolerated dose (MTD) of PF-03084014 when administered twice daily for 21 days ... 1) Patients with advanced solid tumor malignancy (with measurable disease as per Recist for patients enrolled in the expansion ... 3) Patient is ,3 weeks (advanced solid tumor malignancy) or ,2 weeks (T-ALL/LBL) from last anti-cancer treatment (except Hydrea ...
Tumor assessment based on Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 was performed for evaluable tumor ... Patient disposition and primary reasons for study discontinuation. a Patients who received at least three administrations of ... Although Cmax at 4 mg/kg in patients with gastric cancer (part 2) was relatively lower than in patients with solid tumors (part ... patients with HCC had a greater mean body weight than those with gastric cancer or solid tumors. Almost all patients had ...
Cancer: solid tumors. Patients with breast cancer; renal cell carcinoma; pancreatic neuroendocrine tumor; soft tissue sarcoma; ... Primary hyperparathyroidism Patients with hypercalcemia due to primary hyperparathyroidism Serum calcium Traditional. Calcium- ... Patients with breast cancer. Pathological complete response. Accelerated. Mechanism agnostic*. Cancer: solid tumors. Patients ... Patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anti-cancer therapy expected to result in ...
Primary CNS tumor; recurrent/refractory (high/low grade gliomas, medulloblastoma): Limited data available; efficacy results ... Ovarian failure: In premenopausal women with solid tumors receiving adjuvant therapy, the incidence of ovarian failure was 34% ... Tumor burden: Patients with a higher tumor burden had a higher clearance of bevacizumab compared with patients who had a tumor ... Refractory solid tumor: Limited data available: Children and Adolescents: IV: 5 to 15 mg/kg/dose every 2 weeks in a 28-day ...
To assess the preliminary anti-tumor activity of this regimen in patients with advanced, inoperable, or metastatic solid tumors ... PRIMARY OBJECTIVES:. I. To determine the maximum-tolerated dose of entinostat in combination with sorafenib tosylate in ... More From BioPortfolio on "Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or ... Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute ...
The clinicopathologic features and pathogenesis of these tumors have attracted a number of investigations, but the results ... Solid-cystic-papillary tumors (SCPTs) of the pancreas are rare. ... of the primary pancreatic tumors. The tumors were seen in young ... Pancreatic Solid-cystic-papillary Tumor: Clinicopathologic Features in Eight Patients from Hong Kong and Review of the ... Solid-cystic-papillary tumors (SCPTs) of the pancreas are rare. The clinicopathologic features and pathogenesis of these tumors ...
Multivariate analysis of the cohort identified tumor stage (HR 8.39, P , 0.001 for distant disease), tumor type (signet ring HR ... Primary Solid Tumors of the Colon and Rectum in the Pediatric Patient: A Review of 270 Cases. Journal of Surgical Research. ... Primary Solid Tumors of the Colon and Rectum in the Pediatric Patient : A Review of 270 Cases. / Yang, Relin; Cheung, Michael C ... Fingerprint Dive into the research topics of Primary Solid Tumors of the Colon and Rectum in the Pediatric Patient: A Review ...
18 we found that the risk of developing any type of second primary solid tumor in patients with MPNs is significantly higher ... Incidence and risk of second primary solid tumors. Among the 7454 selected patients with MPNs, 626 were diagnosed with solid ... Patients with PV or ET had an 8-year cumulative incidence of second primary solid tumors of ∼14%. Patients with MPNs had a 2 ... Risk of disease transformation and second primary solid tumors in patients with myeloproliferative neoplasms Junshik Hong ...
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PUR... ... Primary Purpose: Treatment. Conditions. Unspecified Adult Solid Tumor, Protocol Specific. Intervention. SarCNU ... S-3304 in Treating Patients With Advanced Solid Tumors. RATIONALE: S-3304 may stop or slow the growth of solid tumors by ... EMD 121974 in Treating Patients With Advanced Solid Tumors. RATIONALE: EMD 121974 may slow the growth of solid tumors by ...
Bortezomib and pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. ... Tumor tissue and blood samples from patients enrolled in the phase II portion of the study. are examined for various biological ... Primary. - Determine the safety, including dose-limiting toxicities, and feasibility of combining. bortezomib with pemetrexed ... disodium in patients with advanced solid tumors. (Phase I). - Assess the overall survival and progression-free survival of ...
... stop the growth of solid tumors by stopping blood flow to the ... Targeted therapy with tumor necrosis factor combined with a ... Primary. - Determine the dose-limiting toxicity and maximum tolerated dose of tumor. vasculature-targeted tumor necrosis factor ... solid tumors.. - Determine the recommended phase II dose of this drug in these patients.. Secondary. - Determine the mechanism ... Phase I Trial of NGR-TNF Administered Every 3 Weeks as a 1 Hour Intravenous Infusion in Patients With Solid Tumor. Trial Phase: ...
A Study of Oral LOXO-292 in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors * Ages: 6 Months to ... prexasertib in treating pediatric patients with solid tumors that have come back after a period of time during which the tumor ... in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors PURPOSE: This phase I trial studies the ... feasible and beneficial to pediatric patients with solid solid tumors or lymphoma that are recurrent or refractory to standard ...
Solid/brain tumor patients (1-18 years). Description: Patients with solid tumor or brain tumor in the 1-18 years old stratum.. ... Primary Completion Date. August 2002. Eligibility Criteria. Inclusion Criteria: - Histologically confirmed high-risk or ... Rescue for High Risk Solid Tumors Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors ... stem cell transplantation plus chemotherapy in patients with high-risk or relapsed solid tumors or brain tumors. - Determine ...
Known prior primary or metastatic brain or meningeal tumors.. *Receiving treatment with immunosuppressive agents, including any ... For the solid tumor expansion cohorts, enrollment is limited to the following solid tumors: melanoma and renal cell carcinoma. ... A Study of CDX-1127 (Varlilumab) in Patients with Select Solid Tumor Types or Hematologic Cancers. Overview. *. Study type. ... as well as patients with select types of solid tumors. ... Tumor must be recurrent or treatment refractory with no ...
The Pan-Cancer analysis encompasses all patients with solid tumors.. (B) Heatmap extending the analysis from (A) to all PMN ... Survival was compared between patients whose primary tumors fell into the highest (red) versus lowest (blue) expression ... Inflammationand PMN Recruitment in PRPL Tumors Occurs Independently of Tumor Cell-Extrinsic Factors and Tumor Cell Senescence ... F) Prevalence of intraluminal debris in 4-week tumors quantified as a percentage of total tumor area (intact epithelium + ...
... with locally advanced or metastatic solid tumors [defined by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1] was ... In feces, M445 was the primary metabolite with only trace amounts of M554 excreted. All other metabolites, including ... Pimasertib has shown potent preclinical antitumor activity and its clinical activity is being investigated in various tumor ... Given that the metabolite profile in patients with solid tumors is consistent with the outcomes from in vitro/in vivo studies ( ...
... you may have access to brain tumor treatments before theyre available elsewhere. See currently available trials. ... A Phase I Study of an Arginine Methyltransferase Inhibitor (PRMT5, GSK3326595) in Patients with Solid Tumors and Non-Hodgkin ... Diseases: Brain Tumors, Primary, Other Trials, Pediatric Brain Tumors, Spine Tumors. *Locations: New York City, Commack, ... A Phase I Study of DCC-2618 in Patients with Advanced Glioma or Gastrointestinal Stromal Tumor (GIST) *Diseases: Gliomas, ...
... myeloma or primary solid tumor, and metastatic bone lesions); (c)BP therapy: start date, treatment duration, type of BP, dosage ... M. Aapro, P. A. Abrahamsson, J. J. Body et al., "Guidance on the use of bisphosphonates in solid tumors: recommendations of an ... About 45% of patients received massive steroids treatment (mostly in myeloma affected patients) and another 20% of patients ... "Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients ...
... and find out how to retain the primary tumors heterogeneity. - Latvija ... Discover our worklow for the generation and culture of primary human tumor cell lines, ... Cultivation of tumor cells from primary patient and xenotransplanted pancreatic tumors. The Pancreas TumorMACS™ Medium has been ... Efficient derivation and expansion of tumor cell cultures from primary tumors. *Preserved parental tumor heterogeneity, tumor- ...
Cancer of Unknown Primary. Investigational Drug Treatment Study for Patients with Selected Solid Tumors. A phase 1-2, open- ... Treatment Study for Patients with Advanced Solid Tumor Malignancies. Phase 1/1b study of MGCD516 in patients with advanced ... Investigational Drug Treatment Study for Patients with Selected Solid Tumors. A phase 1-2, open-label, dose-finding, proof of ... Treatment Study for Patients with Rare Tumors. DART: Dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors. ...
Neuroblastoma is the second most common solid tumor in children. Most tumors arise in the adrenal glands or paravertebral ... patients present with metastatic disease but no primary site can be found despite extensive imaging. We report here a patient ... Educational Case: Primary Osteosarcoma. Academic pathology Petriceks, A. H., Salmi, D. 2019; 6: 2374289518820337 Abstract. The ... Neuroblastoma of Unknown Primary Site With Periorbital Bone Metastasis in a Child PEDIATRIC BLOOD & CANCER Salmi, D., Patel, C ...
Cabozantinib S-Malate Crizotinib Savolitinib or Sunitinib Malate in Treating Patients With Locally Advanced or Metastatic ... I. To compare Response Evaluation Criteria in Solid Tumors (RECIST) response rate (RR; defined as the combined rate of ... PRIMARY OBJECTIVES: I. To compare progression-free survival (PFS) in patients with metastatic papillary renal cell carcinoma ( ... Cabozantinib s-malate, crizotinib, savolitinib, and sunitinib malate may stop the growth of tumor cells by blocking some of the ...
  • In this phase I study, the disposition and biotransformation of 14 C-radiolabeled pimasertib was investigated in six patients with locally advanced or metastatic solid tumors ( NCT01713036 ). (
  • CHICAGO - Taselisib demonstrated preliminary clinical activity and exhibited an acceptable safety profile as monotherapy for patients with PIK3CA -mutated locally advanced or metastatic solid tumors, according to results of a basket study presented at American Association for Cancer Research Annual Meeting. (
  • This is an open-label Phase 1b/2 multicenter study of rebastinib (DCC-2036) in combination with carboplatin designed to evaluate the safety, tolerability, and pharmacokinetics (PK) in patients with advanced or metastatic solid tumors. (
  • Histologically or cytologically confirmed diagnosis of advanced or metastatic solid tumors that harbor an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. (
  • For patients enrolled on the Phase II portion of the trial Progression Free Survival (PFS) was measured from the percentage of patients that were still alive, without evidence of disease progression for 6 months following the initiation of treatment. (
  • For patients enrolled on the Phase II portion of the trial the time to progression was measured as the time from when the patient started treatment to the time the patient is first recorded as having disease progression or the date of death if the patient dies due to causes other than disease progression. (
  • Patients will continue on therapy as long as they are not experiencing toxicities and there is no evidence of disease progression. (
  • Evaluate the overall response rate (Response Evaluation Criteria in Solid Tumors [RECIST] v.1.1) and the progression free survival of patients enrolled on the study. (
  • Assess the overall survival and progression-free survival of these patients. (
  • Patients are followed every 8 weeks until disease progression or the start of a new anticancer treatment. (
  • Determine response or time to disease progression in patients treated with this regimen. (
  • By inducing tumor cell detachment from the basement membrane, PMNs impeded early-stage tumor growth and retarded malignant progression. (
  • I. To compare progression-free survival (PFS) in patients with metastatic papillary renal cell carcinoma (mPRCC) treated with sunitinib malate (sunitinib) to PFS in patients with mPRCC treated with MET kinase inhibitors. (
  • This study aimed to analyze the treatment outcomes, particularly infield progression, and severe late toxicity rates after reRT for recurrent rectal cancer and further identify a subgroup of patients who may optimally benefit from reRT. (
  • Desmoplastic tumor stroma characterizes the primary tumor in pancreatic ductal adenocarcinoma, but its role in tumor progression and metastasis is less clear. (
  • The HER3 coreceptor plays an essential role in HER2-mediated transformation, tumor progression, and drug resistance. (
  • The DECISION trial results show sorafenib's ability to extend progression-free survival compared to placebo in patients with this type of advanced thyroid cancer,' said Marcia Brose, MD, PhD, assistant professor in the Department of Otorhinolarlyngology: Head and Neck Surgery and the division of Hematology/Oncology in the Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania. (
  • Sorafenib significantly extended progression-free survival (PFS), the primary endpoint of the study. (
  • Patients whose tumors have MYCN amplification tend to have rapid tumor progression and poor prognosis, even in the setting of other favorable factors such as low-stage disease or 4S disease. (
  • Patients were treated with LENVIMA 20 mg orally once daily until unacceptable toxicity or disease progression in combination with KEYTRUDA 200 mg intravenously every three weeks until unacceptable toxicity or disease progression for up to 35 cycles (approximately two years). (
  • Median PFS was 4.2 months (range: 3.5 to 6.3), with 73.8% of patients experiencing disease progression or death, and the nine-month PFS rate was 26.2% (95% CI: 17.4-35.9). (
  • Patients received mCRC combination dosing of Opdivo (3 mg/kg) plus Yervoy (1 mg/kg) every three weeks for four doses, followed by Opdivo (3 mg/kg) every two weeks until disease progression, death or unacceptable toxicity. (
  • Other key endpoints include duration of response (DOR), overall survival (OS), progression-free survival (PFS), disease control rate (DCR), ORR per blinded independent central review (BICR), patient reported outcomes and safety. (
  • ADR: IPSEY) today announced that the New England Journal of Medicine has published clinical trial results showing that Somatuline ® Autogel ® / Somatuline ® Depot ® (lanreotide) Injection 120 mg (referred to as Somatuline ® ) achieved statistically significant prolongation of progression free survival (PFS) over placebo in patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs). (
  • "This is potentially exciting news for physicians treating GEP-NETs, as the data showed anti-tumor activity and a delay in disease-progression in patients treated with Somatuline ® Depot ® ," said Dr. Alexandria Phan, CLARINET investigator, Director of GI Medical Oncology at Houston Methodist Cancer Center. (
  • 1 In ELOQUENT-3, a randomized, open-label, Phase 2 trial, EPd demonstrated benefit in patients with relapsed or refractory multiple myeloma, doubling both median progression-free survival (PFS) and overall response rate (ORR) versus pomalidomide and dexamethasone (Pd). (
  • Empliciti plus pomalidomide and dexamethasone has been proven to extend the time that certain patients live without disease progression, giving health care professionals an effective new tool to tackle this relentless cancer," 1,2 said Joseph E. Eid, M.D., senior vice president and head of Medical, Bristol-Myers Squibb. (
  • This new regimen of elotuzumab combined with pomalidomide and dexamethasone not only extended the time to disease progression versus a standard of care but also doubled the response rate in some patients whose prior treatments had failed them. (
  • Recent studies have revealed that there exists a small distinct population of cancer stem cells in breast tumors, which could initiate a tumor, mediate progression and resist to chemotherapy and radiation, contributing to treatment failure and disease relapse [ 3 ]. (
  • Key secondary endpoints were progression-free survival (PFS), overall survival, efficacy by independent radiologic review, safety, health-related quality of life, and molecular characterization of tumor tissue. (
  • Two patients with ROS1 wild-type sequences assessed by DNA sequencing had progression as best response. (
  • The primary endpoint is progression free survival. (
  • The results also highlighted that sotorasib is the first KRAS G12C inhibitor to show progression-free survival (median of 6.8 months) in a Phase 2 study, which is consistent with earlier Phase 1 results in previously treated patients with KRAS G12C- mutated advanced NSCLC. (
  • We are interested in identifying key driver genes and their signaling mechanisms responsible for tumor initiation and progression. (
  • While one patient in this trial showed no disease progression after the 12-week study period, the THINK trial will use NKR-2 in a higher concentration in order to improve efficacy. (
  • 4. To document any anti-tumor activity with PF-03084014 alone in patients with relaspsed or refractory T-ALL/LBL. (
  • To assess the preliminary anti-tumor activity of this regimen in patients with advanced, inoperable, or metastatic solid tumors or refractory/relapsed AML. (
  • In SCID or SCID beige mice, anti-tumor effects of CTX140 1q6d are reduced, reinforcing the therapeutic contribution of the adaptive and innate immune systems. (
  • This work sheds light on the potential use of metronomic CTX for the treatment of breast cancer, in particular using the quasi-weekly regimen, but also underscores the complexity of the anti-tumor mechanisms and potential to improve immune checkpoint therapy efficacy. (
  • The primary objective of the study is to describe the anti-tumor activity and safety of seribantumab specifically in patients with an NRG1 gene fusion. (
  • The anti-tumor activity seen across cancer types and entrectinib's ability to treat bulky CNS disease, particularly important given the propensity for many solid tumors to metastasize to the brain, is extremely encouraging," said Alexander Drilon, M.D., Memorial Sloan Kettering Cancer Center, one of the lead co-authors on the paper. (
  • Entrectinib demonstrated robust anti-tumor activity in both studies across the twenty-five patients who harbored recurrent gene fusions involving NTRK1/2/3 , ROS1 or ALK , had not received prior TKI treatment targeting these fusions and were treated at doses that achieved exposures consistent with the recommended Phase 2 dose of 600 mg of entrectinib daily. (
  • The Opdivo and Yervoy combination has demonstrated efficacy across tumors in a broad range of patients, and we are very encouraged to see that the complementary effect of this combination has the potential to increase anti-tumor activity in patients with dMMR or MSI-H metastatic colorectal cancer," added Ian M. Waxman, M.D., development lead, Gastrointestinal Cancers, Bristol-Myers Squibb. (
  • A Comprehensive Review of Denosumab for Bone-Metastasis in Patients with Solid Tumors. (
  • In this review, we aimed to show the clinical data of denosumab treatment and discuss its advantages for the management of patients with solid tumors and bone-metastasis. (
  • A Genitourinary Cancer-specific Scoring System for the Prediction of Survival in Patients with Bone Metastasis: A Retrospective Analysis of Prostate Cancer, Renal Cell Carcinoma, and Urothelial Carcinoma. (
  • The aim of this study was to develop a risk scoring system specific to patients with bone metastasis of genitourinary cancer. (
  • This study included 180 patients with bone metastasis of three major types of genitourinary cancer: prostate cancer (n=111), renal cell carcinoma (n=43,), and urothelial carcinoma (n=26). (
  • Kaplan-Meier analyses were used to quantify the cumulative incidence of bone metastasis with follow-up for each patient from the index date to the earliest of the following events: last clinic visit in the OSCER database, occurrence of a new primary tumor or bone metastasis, end of study (12/31/2014). (
  • Cumulative incidence of bone metastasis increased by stage at diagnosis, with markedly higher incidence among patients diagnosed at Stage IV of whom11% had bone metastases diagnosed within 30 days. (
  • Tumors are evolving as part of metastasis and under therapy," said Arul Chinnaiyan, M.D., Ph.D., director of the Michigan Center for Translational Pathology, in the release. (
  • However, Dpc4 immunolabeling status of carcinoma tissues harvested at autopsy, a sensitive marker of DPC4 genetic status, was highly correlated with the presence of widespread metastasis but not with locally destructive tumors ( P = .007). (
  • Although comprehensive therapies including surgery, chemotherapy, radiotherapy, endocrine and targeted therapy, even the novel immunotherapy have been applied to breast cancer, recurrence and metastasis still occur years after therapies in many patients, leading to a high mortality [ 2 ]. (
  • Now the most used BCSC markers including CD44 + , CD24 - , aldehyde dehydrogenase (ALDH) + , EpCAM + , LGR5 + [ 5 , 7 , 8 ], and identification of these markers in tissue clinically were demonstrated meaningful in predicting tumor response, metastasis and survival. (
  • While patients with untreated colorectal metastasis to the liver have no five year survival, patients undergoing surgical resection have approximately a 25-30% five year survival. (
  • Supinoxin™ (RX-5902) is an orally administered, potential first-in-class, small molecule modulator of the β-catenin pathway - a key biological pathway that is activated in tumor cells leading to production of multiple cancer oncogenes and tumor proliferation and metastasis. (
  • Consequently, we have developed various genome-based signatures linked to venous metastasis, tumor recurrence, p53 mutations, stem cell features, male dominance or treatment response. (
  • the secondary objective was to determine response rate in patients whose tumors carry BRCA mutations. (
  • [ 1 ] In contrast, infants whose tumors have a DNA index of 1 are less responsive to the latter combination and require more aggressive therapy. (
  • In so doing they discovered that patients whose tumors have spread harbor significantly more mutations-and more diverse mutations-than what's generally found in the primary tumor. (
  • The next step for the researchers is to analyze treatment outcomes for the patients whose tumors were sequenced. (
  • The combination of Opdivo and Yervoy may represent an important advance for these distinct biomarker-defined patients, who historically have poorer outcomes compared to metastatic colorectal cancer patients whose tumors are mismatch repair proficient or microsatellite stable. (
  • This can potentially save patients that have responded well to non-surgical treatment from surgery (regarding esophageal cancer) and/or lead to a timely change to other forms of treatment in those patients whose tumors did not respond to standard treatment. (
  • Abraxane™) in patients with advanced solid tumor malignancies. (
  • To determine the maximum tolerated dose (MTD) of PF-03084014 when administered twice daily for 21 days alone in patients with advanced malignancies. (
  • 3. To evaluate the pharmacodynamics of PF-03084014 in patients with advanced malignancies. (
  • 6. To evaluate mechanisms of sensitivity and resistance to PF-03084014 in patients with advanced malignancies. (
  • This study aimed to elucidate patterns of disease transformation to secondary myelofibrosis (SMF) or secondary acute myeloid leukemia (SAML) and the development of second primary malignancies in South Korean patients with BCR-ABL1 -negative myeloproliferative neoplasms (MPNs). (
  • OBJECTIVES: I. Determine the maximum tolerated dose of SarCNU in patients with advanced solid malignancies. (
  • CAR-T cell therapy has achieved gratifying breakthrough in hematological malignancies and promising outcome in solid tumor as showed in various clinical trials. (
  • Second Primary Malignancies (SPM): Higher incidences of SPM were observed in a controlled clinical trial of patients with multiple myeloma receiving EMPLICITI. (
  • Results There were 229 (71%) patients with solid tumors and 96 (29%) patients with hematological malignancies. (
  • Empliciti with pomalidomide and dexamethasone is associated with Warnings and Precautions related to: infusion reactions, infections, secondary primary malignancies, hepatotoxicity, interference with determination of complete response, pregnancy/females and males of reproductive potential and adverse reactions. (
  • Must have one of the following solid tumors: Advanced or metastatic clear cell RCC or non-clear cell RCC, urothelial cancer, small cell lung cancer, advanced soft tissue or bone sarcoma, metastatic melanoma, or mismatch-repair-deficient malignancies. (
  • Repotrectinib will provide opportunities in clinic to stop the abnormal cell signaling of ALK/ROS1/TRKs in solid malignancies, and overcome your body's natural resistance to treatment of advanced solid tumors harboring ALK, ROS1, or NTRK1-3 rearrangements. (
  • The Medical Oncology Track is ideal for fellows with a strong interest in an academic career in solid tumors and/or hematologic malignancies. (
  • This unique inpatient/outpatient consult service provides fellows with the basics of diagnosis and chemotherapeutic management of patients with a wide variety of hematologic malignancies. (
  • This intensive inpatient service provides fellows with a unique training experience for the inpatient care and chemotherapeutic management of patients with solid malignancies. (
  • Salivary gland tumors are rare and account for 0.5% of all malignancies in children and adolescents. (
  • Most of IV prescriptions of more potent BPs are written for patients affected by myeloma or bone metastases from solid cancer [ 1 ]. (
  • TSD was decreased in solid organ (0.12) and lymph node metastases (0.22) ( P =0001). (
  • Bone metastases commonly occur in conjunction with solid tumors, and are associated with serious bone complications. (
  • The current study was conducted to estimate the incidence of bone metastases reflecting the more recent treatment landscape for patients with solid tumors. (
  • Specifically, we estimated the cumulative incidence proportion of clinically-identified bone metastases for all solid tumors combined and by tumor type using electronic medical records (EMR) data from oncology clinics in the United States (US). (
  • Additionally, staging of the tumor can be performed to classify the extent of the lesion, regional lymphadenopathy, vascular involvement, and metastases. (
  • In three NTRK1/2/3- rearranged solid tumors (NSCLC, MASC and colorectal cancer) with RECIST-measurable disease, the objective response rate (ORR) was 100%, including complete resolution of brain metastases in the patient with NSCLC. (
  • This study revealed that ARL4C is highly expressed in primary hepatocellular carcinoma (HCC) tumors and colorectal cancer liver metastases, and that ARL4C expression is associated with poor prognosis for these cancers. (
  • Primary tumors and metastases may be treated microinvasively through heating (thermal ablation), freezing (cryoablation) and direct alcohol injection. (
  • RATIONALE: Drugs used in chemotherapy, such as temozolomide, vincristine, and irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. (
  • Giving more than one drug (combination chemotherapy) may kill more tumor cells. (
  • Methods This was a multicenter, multiple-dose, open-label study in Japanese patients aged ≥20 years with solid tumors, including gastric cancer (GC) or advanced hepatocellular carcinoma (HCC), who had failed standard chemotherapy. (
  • Treatment of platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer (in combination with paclitaxel, doxorubicin [liposomal], or topotecan) in patients who received no more than 2 prior chemotherapy regimens. (
  • RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. (
  • Phase I trial to study the effectiveness of chemotherapy using sarCNU in patients who have advanced solid tumors. (
  • Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. (
  • OBJECTIVES: - Determine the dose-limiting toxicity of amifostine chemoprotection with peripheral blood stem cell transplantation plus chemotherapy in patients with high-risk or relapsed solid tumors or brain tumors. (
  • On day 6 of G-CSF administration, patients undergo peripheral blood stem cell (PBSC) harvest followed by chemotherapy. (
  • Because doctors from different disciplines work together closely through our collaborative Brain Tumor Center, many of our clinical trials combine different treatment approaches, such as radiation therapy and chemotherapy. (
  • A randomized, double-blind, phase III clinical trial of neoadjuvant chemotherapy with atezolizumab or placebo in patients with triple-negative breast cancer followed by adjuvant continuation of atezolizumab or placebo. (
  • At Children's, your child will have access to the most current national and international solid tumor oncology treatment protocols for chemotherapy and radiation through the Children's Oncology Group (COG). (
  • A possible way to improve these limited immunotherapy benefits include combination with other types of therapy (similar to other types of cancer patients treated with PD-1 or PD-L1 antibodies) such as chemotherapy, vascular endothelial growth factor (VEGF) pathway targeting drugs, or other immune checkpoint inhibitors that ideally do not substantially increase overall toxicity. (
  • Dr. Thomas said, "Together, this work highlights the vulnerability of small-cell tumors to ATR inhibition as a result of high levels of replication stress, and the potential for the combination of berzosertib and topotecan to yield durable tumor responses among chemotherapy-resistant patients. (
  • Dr. Giuseppe Giaccone, associate director for Clinical Research at the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine in New York City, told Reuters Health by email, "The use or ATR inhibitors with chemotherapy is logical, especially in a tumor type like SCLC where proliferation is very high and chemotherapy has a very high success rate, at least initially. (
  • The results in the small group of patients treated with this combination are of interest," he said, "especially because activity was observed in platinum-resistant patients, where chemotherapy usually has poor activity. (
  • In this small study, the ATR compound increased the myelosuppression caused by chemotherapy, and most patients did not receive immunotherapy before (immunotherapy has now become standard first-line treatment). (
  • Resected patients received no adjuvant chemotherapy. (
  • The patients received a variety of concurrent medications, including conventional chemotherapy and biologic therapy. (
  • only one received adjuvant chemotherapy (solid tumor). (
  • The only patient with a subtotally resected solid lesion who did not have recurrence received adjuvant chemotherapy. (
  • We conducted a retrospective analysis to evaluate the effect of tumor location on prognosis and efficacy of biological agents (anti-EGFR, Cetuximab and Panitumumab, or anti-VEGF, Bevacizumab) added to first-line chemotherapy in patients with RAS wild-type (wt) mCC. (
  • Patients with newly diagnosed RAS wt mCC candidates to first-line chemotherapy with anti-EGFRs or Bevacizumab were selected. (
  • We found evidence in support of the impact of tumor location in RAS wt mCC treated with first-line chemotherapy in association with targeted therapy. (
  • There are currently no FDA-approved treatments for TNBC and there is no standard chemotherapy treatment for patients. (
  • Prior to the trial, 81% of patients had progressed on both platinum-based chemotherapy and PD1/L1 inhibitors, with the remainder progressing after having received one of these therapies. (
  • This co-mutation has been associated with poor outcomes in NSCLC patients treated with checkpoint inhibitors and chemotherapy. (
  • Salivary gland tumors may occur after radiation therapy and chemotherapy are given for treatment of primary leukemia or solid tumors. (
  • This phase I trial studies the side effects and best dose of pembrolizumab and recombinant interleukin-12 in treating patients with solid tumors. (
  • This phase I trial studies the side effects and the best dose of navitoclax when given together with sorafenib tosylate in treating patients with solid tumors that have returned (relapsed). (
  • This phase I trial studies the side effects and best dose of olaparib and onalespib when given together in treating patients with solid tumors that have spread to other places in the body or cannot be removed by surgery or ovarian, fallopian tube, primary peritoneal, or triple-negative breast cancer that has come back. (
  • The objective response rate was 36% as measured by Response Evaluation Criteria in Solid Tumors, achieving the primary efficacy endpoint. (
  • PFS was evaluated by an independent radiological review committee using modified Response Evaluation Criteria in Solid Tumors (mRECIST). (
  • The primary endpoint is ORR per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as assessed by blinded independent central review (BICR). (
  • The primary endpoint is investigator-assessed objective response rate (ORR) using the Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1. (
  • Response evaluation criteria in solid tumors (RECIST) is a set of published rules that define when tumors in cancer patients improve ("respond"), stay the same ("stabilize"), or worsen ("progress") during treatment. (
  • TSD was no different in the primary tumors of patients who had localized compared to metastatic disease. (
  • Despite advances in surgical treatment of primary neoplasms and aggressive therapies, most cancer patients die as a result of metastatic disease. (
  • Unfortunately, approximately 70-80% of patients older than 18 months present with metastatic disease, usually in the lymph nodes, liver, bone, and bone marrow. (
  • At autopsy, 30% of patients died with locally destructive pancreatic cancer, and 70% died with widespread metastatic disease. (
  • For patients with widespread metastatic disease, systemic tumor-targeting molecular radiotherapy (MRT) approaches are needed. (
  • NSCLC accounts for 80%-85% of all lung cancers, and most patients (66%) have advanced or metastatic disease at initial diagnosis. (
  • This phase I trial studies the side effects and best dose of iodine I 131 monoclonal antibody 8H9 in treating patients with small round cell tumors that cause or form adhesions or fibrous connective tissue within a tumor (desmoplastic) and other solid tumors involving the peritoneum. (
  • Perform laboratory correlative studies on tumor tissue and blood samples to investigate potential predictors of response. (
  • Tumor tissue and blood samples from patients enrolled in the phase II portion of the study are examined for various biological markers. (
  • L) Uterine PMN tissue densities through the course of PRPL tumor development, as determined by flow cytometry. (
  • D and E) Representative 4-week uterine tissue sections co-stained for E-cad to identify tumor cells and Ly6G to identify PMNs (n = 6 mice per group). (
  • To improve this complex procedure, we developed a workflow allowing for rapid and flexible tissue preparation for subsequent derivation of primary tumor cell cultures using our novel Pancreas TumorMACS™ Medium. (
  • The gentleMACS™ Dissociator in combination with the Tumor Dissociation Kit, human ensures rapid and standardized dissociation of tissue samples into single-cell suspensions. (
  • Single-cell suspensions from human melanoma tissue were prepared using the Tumor Dissociation Kit in combination with the gentleMACS™ Dissociator. (
  • Get more information on storage and dissociation of tumor tissue here. (
  • This randomized phase II trial studies how well cabozantinib s-malate, crizotinib, savolitinib, or sunitinib malate work in treating patients with kidney cancer that has spread from where it started to nearby tissue or lymph nodes or to other places in the body. (
  • 80% tumor) of paired P tumor and M lesions from all 10 patients, as well as in normal tissue from 6 of these cases, was analyzed. (
  • Further, while the VHL genotype differed between the primary tumor in different kidneys or multiple metastatic lesions in the same patient, the VHL germline genotype in the normal adjacent tissue was always wild-type irrespective of the VHL gene status in the P tumor. (
  • These results demonstrate for the first time that the VHL gene status can be different between paired primary and metastatic tissue in patients with CCRCC. (
  • A tumor is tissue that forms when cells grow and divide uncontrollably and no longer function properly. (
  • Investigators centrally assessed archival or fresh tumor tissue for PIK3CA mutation amplification. (
  • Tissue sections of primary tumors from 57 patients who underwent curative resections and 46 primary and metastatic tumors from 15 patients with metastatic pancreatic cancer were digitally annotated for tumor epithelium and tumor stroma, reviewed by a pathologist, and quantified using the Spectrum WebScope. (
  • Although non-cancerous brain tumors usually grow slower than cancerous brain tumors, they may damage and press against normal brain tissue or the spine or spinal cord as they grow, potentially causing symptoms. (
  • Primary solid tumors and normal adjacent control samples were from CHTN (The Cooperative Human Tissue Network) or the National Disease Research Interchange. (
  • We need to biopsy the metastatic tumors and then suggest therapies, rather than using archival tissue from the primary tumor. (
  • The Tissue Factor antigen target is overexpressed in the vast majority of patients with cervical cancer and in many other solid tumors, including ovarian, lung, pancreatic, colorectal and head and neck. (
  • In cancer biology, Tissue Factor is a protein involved in tumor signaling and angiogenesis. (
  • Based on its high expression on many solid tumors and its rapid internalization, Tissue Factor was selected as a target for an ADC approach. (
  • However, breast cancer stem cells (BCSCs) only account for about 2% of breast cancer cells and is hard to be isolated from human tumor tissue. (
  • Nevertheless, the only approach to acquire tissue samples is biopsy or surgery that is invasive, moreover, samples could not be taken repeatedly from the breast tumor. (
  • This surrogate endpoint table includes surrogate endpoints that sponsors have used as primary efficacy clinical trial endpoints for approval of new drug applications (NDAs) or biologics license applications (BLAs). (
  • The table also includes surrogate endpoints that may be appropriate for use as a primary efficacy clinical trial endpoint for drug or biologic approval, although they have not yet been used to support an approved NDA or BLA. (
  • Tolerability and safety served as the primary endpoint. (
  • With a median of 13.4 months of follow-up, the primary endpoint of objective response rate (ORR) per investigator assessment was 55% (95% CI: 45.2 to 63.8). (
  • The primary endpoint of the trial is objective response rate as assessed by independent review. (
  • Only patients with measurable disease at baseline should be included in protocols where objective tumor response is the primary endpoint. (
  • Results: Overall, 270 patients with malignant tumors of the lower gastrointestinal tract were identified. (
  • Abnormal blood vessels and hypoxic and necrotic regions are common features of solid tumors and related to the malignant phenotype and therapy resistance. (
  • Other tumors may be cancerous or malignant, and are referred to as sarcomas. (
  • One of the devastating aspects of cancer is the propensity of cells from malignant neoplasms which disseminate from their primary site to distant organs and develop into metastatic cancers. (
  • Solid pseudopapillary tumor of the pancreas (SPTP) is a rare neoplasm and is considered to have low-grade malignant potential. (
  • Kaste SC, Hedlund G, Pratt CB: Malignant parotid tumors in patients previously treated for childhood cancer: clinical and imaging findings in eight cases. (
  • Malignant tumors of the parotid gland in children: incidence and outcomes. (
  • These tumors are most frequently benign but may be malignant, especially in young children. (
  • Many oncologists in their daily clinical practice follow their patients' malignant disease by means of repeated imaging studies and make decisions about continuing therapy on the basis of both objective and symptomatic criteria. (
  • These characteristics are required to produce a malignant tumor. (
  • Treatment of stage III or IV epithelial ovarian, fallopian tube, or primary peritoneal cancer following initial surgical resection (in combination with carboplatin and paclitaxel, followed by single-agent bevacizumab). (
  • Treatment of platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer (in combination with carboplatin and paclitaxel or with carboplatin and gemcitabine and then followed by single-agent bevacizumab). (
  • Histologic diagnosis of either a B-cell or T-cell hematologic malignancy known to express CD27 or one of the following solid tumors: metastatic melanoma, renal (clear) cell carcinoma, hormone-refractory prostate adenocarcinoma, ovarian cancer, colorectal adenocarcinoma or non-small cell lung cancer. (
  • In the Phase 2 LEAP-005 trial, KEYTRUDA plus LENVIMA demonstrated an ORR that ranged from 9.7-32.3% (95% CI: 2.0-51.4) in previously treated patients with triple-negative breast cancer (TNBC), ovarian cancer, gastric cancer, colorectal cancer (non-microsatellite instability-high [non-MSI-H]/mismatch repair proficient [pMMR]), glioblastoma multiforme (GBM) and biliary tract cancer (BTC). (
  • Supinoxin™ has been evaluated in a Phase I dose-escalation study in patients with a diverse range of metastatic, treatment-refractory tumors including breast, ovarian, colorectal and neuroendocrine tumors. (
  • Since 2005 a multidisciplinary study group collected data of cases of ONJ in patients treated with Bisphosphonates (BP) and observed in oncology and hematology centers of a regional network. (
  • Electronic medical records (OSCER, Oncology Services Comprehensive Electronic Records, 569,000 patients, 52 US cancer centers) were used to identify patients ≥18 years with a solid tumor diagnosis recorded between 1/1/2004 and 12/31/2013, excluding patients with hematologic tumors or multiple primaries. (
  • Elevation Oncology is founded on the belief that every patient with cancer deserves to know what is driving the growth of their disease and have access to therapeutics that can stop it. (
  • To complete their analysis, the Michigan scientists sequenced both the DNA and RNA from biopsies of metastatic tumors, which were taken from patients enrolled in the Michigan Oncology Sequencing Program. (
  • SAN DIEGO--( BUSINESS WIRE )-- Ignyta , Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, today announced that updated results from two Phase 1 trials of entrectinib -the company's investigational, orally available, CNS-active tyrosine kinase inhibitor targeting tumors that harbor TRK, ROS1 or ALK fusions-were published in the journal Cancer Discovery . (
  • These results demonstrate that Opdivo plus Yervoy provide durable clinical benefit in patients with dMMR or MSI-H metastatic colorectal cancer," said Thierry André, M.D., Head of the Medical Oncology Department in St. Antoine Hospital, Assistance Publique Hôpitaux de Paris. (
  • We are continuing to increase our understanding of the benefit of Immuno-Oncology based combinations and look forward to further evaluating the potential of our immunotherapy treatments in colorectal cancer patients. (
  • While significant advances have been made in the treatment and prevention of cervical cancer, there remains a need for targeted agents that are effective for patients who progress or relapse after standard treatments," said Robert Coleman, M.D., FACOG, FACS, Professor of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center , Houston, TX and principal investigator of the innovaTV 204 trial. (
  • Today's approval reinforces the importance of Immuno-Oncology in blood cancers and expands the role of Empliciti to address the needs of relapsed or refractory multiple myeloma patients. (
  • 2 Department of Gynecology Oncology, The Tumor Affiliated Hospital of Harbin Medical University, Harbin, China. (
  • In a study focused on the phase III COMBI-AD trial reported in The Lancet Oncology, Schadendorf et al found no difference in patient-reported outcomes with adjuvant dabrafenib plus trametinib vs placebo in patients with resected BRAF V600E- or BRAF V600K-mutant stage III melanoma. (
  • PRINCETON, N.J.--( BUSINESS WIRE )-- Bristol-Myers Squibb Company (NYSE:BMY) today announced new data from a cohort of the phase 2 CheckMate -142 trial evaluating Opdivo (nivolumab) and Yervoy (ipilimumab) for the treatment of patients with DNA mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC). (
  • In addition, subcutaneous injection of ARL4C ASO was effective in reducing the growth of primary HCC and metastatic colorectal cancer in the liver of immunodeficient mice. (
  • In colorectal cancer the liver is the initial site of spread in more than one-third of patients, and is involved in more than two-thirds at the time of death. (
  • For patients enrolled on the Phase II portion of the trial the One-year survival was measured as the percentage of patients alive 1 year after their treatment in the trial. (
  • This screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival. (
  • Surgical resection significantly improves survival for most pediatric tumors of the lower gastrointestinal tract. (
  • Patients with SMF had an overall survival comparable to those with PMF with less risk of developing SAML. (
  • Compared with patients with PMF, patients with SMF had a similar overall survival with a lower risk of developing SAML. (
  • To compare overall survival (OS) in patients with mPRCC treated with sunitinib to OS in patients with mPRCC treated with putative MET inhibitors. (
  • A recent phase III clinical trial in high-risk pediatric rhabdomyosarcoma patients showed improved survival when vinorelbine and continuous daily low-dose metronomic CTX was used as maintenance therapy after effective induction therapy, leading to this protocol being adopted as a new standard of care for this indication 6 . (
  • The association of TSD with overall and relapse-free survival was adjusted for tumor grade, T, N, overall stage, American Society of Anesthesiologists score, and smoking status. (
  • Essential for tumor cell survival and overexpressed in most cancers, survivin is a promising target for anti-cancer immunotherapy. (
  • Importantly, NRG1 gene fusions are mutually exclusive with other known driver mutations and are considered a unique oncogenic driver event essential for tumor cell survival. (
  • Advances in treatment have increased the overall 5-y survival rate to approximately 80%, but improvements for several solid tumors have plateaued within the past 10-20 y ( 2 ). (
  • External-beam radiotherapy plays an integral role in the treatment regimen for most pediatric solid tumors and has significantly contributed to improvements in overall survival over the decades. (
  • Despite recent treatment advances, survival outcomes remain poor for patients with advanced stage non-small cell lung cancer on second and third-line therapies with the KRAS G12C mutation. (
  • Indeed, in a collaborative analysis with Almac Diagnostics, endosialin was expressed to a greater extent in an angio-immune/mesenchymal subgroup than in other patients, thus suggesting that endosialin might play an important role in gifting a mesenchymal profile to cancers. (
  • South Korean patients with MPNs had a significantly higher risk of developing second primary solid tumors than that of the general population, particularly for kidney, prostate, brain, liver, and lung cancers. (
  • The study enrolls patients with hematologic cancers (certain leukemias and lymphomas), as well as patients with select types of solid tumors. (
  • Pimasertib is currently in clinical development for the treatment of a number of solid and hematologic cancers. (
  • and those with PIK3CA -mutant tumors not otherwise specified, excluding colorectal, breast and non-small cell lung cancers. (
  • SCLC is one of the small-cell neuroendocrine cancers (SCNCs) occurring in various primary sites that lack effective treatments. (
  • These findings highlight replication stress as a potentially transformative vulnerability of SCNCs, paving the way for rational patient selection in these cancers, now treated as a single disease," the authors state. (
  • The primary and secondary outcomes were the odds ratios (ORs) for all second cancers and for secondary leukemia/ myelodysplasia, respectively. (
  • Second cancers were reported in 143 patients, including 75 patients in the cisplatin arm and 68 in the non-cisplatin arm (raw event rates of 1.91 and 1.96%, respectively). (
  • They also suggest that therapeutic inhibitors of HER3 should be used in combination with HER2 inhibitors and PI3K pathway inhibitors in patients with HER2- and PI3K-dependent cancers. (
  • These are called primary brain cancers. (
  • This phase I trial was conducted to test whether vaccine EMD640744, a cocktail of five HLA class I-binding survivin peptides in Montanide(®) ISA 51 VG, promotes anti-survivin T-cell responses in patients with solid cancers. (
  • Cancers that have spread are far more genetically diverse than primary tumors, scientists have discovered. (
  • Scientists at the University of Michigan wanted to understand what makes solid tumors spread-and, by extension, how the growing selection of personalized drugs could best be employed in patients whose cancers have metastasized. (
  • So they created their own gene-sequencing technique and tested it on 500 patients with cancers that had metastasized. (
  • The scientists hypothesized that the cancers developed more mutations over time and in response to drugs used to treat the tumors. (
  • These new data from our LEAP clinical program show encouraging activity across several aggressive cancer types and expand our knowledge about the potential of KEYTRUDA plus LENVIMA to help a range of patients with these cancers," said Dr. Scot Ebbinghaus, Vice President, Clinical Research, Merck Research Laboratories. (
  • A comprehensive study of pancreatic cancers from patients who have succumbed to their disease has the potential to greatly expand our understanding of the most lethal stage of this disease and identify novel areas for intervention. (
  • These results suggest that ARL4C ASO represents a novel targeted nucleic acid medicine for the treatment of primary and metastatic liver cancers. (
  • To date, the company has recruited two patients with solid tumors, with plans to assess the CAR-T therapy candidate - NKR-2 - in five solid tumors, as well as two hematological cancers. (
  • While CAR-T immunotherapies utilizing the CD19 protein can be highly effective against hematological cancers, they are not as useful when it comes to solid tumor types. (
  • Determine, preliminarily, the efficacy of the combination of bortezomib and pemetrexed disodium in patients with advanced solid tumors. (
  • A multi-centre, open-label, randomized clinical trial comparing the efficacy and safety of the antibody-drug conjugate SYD985 to physician's choice in patients with HER2-positive unresectable locally advanced or metastatic breast cancer. (
  • Early signs of efficacy are encouraging and multiple expansion cohorts are ongoing in a range of tumors. (
  • The primary objective was to compare immunologic efficacy of EMD640744 at doses of 30, 100, and 300 μg. (
  • Vaccination with EMD640744 elicited T-cell responses against survivin peptides in the majority of patients, demonstrating the immunologic efficacy of EMD640744. (
  • 2 , 3 A recent study indicated an alarming reluctance in the medical community to proceed to potentially curative surgery in patients with early-stage pancreatic cancer, despite numerous guidelines that support pancreatectomy as the primary treatment modality for localized disease, indicating the pervasiveness of negative attitudes regarding the efficacy of resection and/or treatment for this disease. (
  • Seattle Genetics, Inc. (Nasdaq:SGEN) today announced dosing of the first patient in the phase 2 innovaTV 204 clinical trial evaluating the efficacy, safety and tolerability of tisotumab vedotin as monotherapy for patients with recurrent and/or metastatic cervical cancer who have relapsed or progressed after standard of care treatment. (
  • Here we present data on efficacy and safety of a prospective phase II trial evaluating crizotinib in European ROS1-positive patients (EUCROSS). (
  • Four patients were excluded from efficacy analysis. (
  • The study will evaluate the safety and efficacy of Supinoxin™ in patients with metastatic TNBC who have failed prior treatments. (
  • The Phase IIa clinical proof-of-concept study is an open-label evaluation of the safety and efficacy of Supinoxin™ monotherapy in patients with metastatic triple negative breast cancer who have failed multiple prior chemotherapeutic regimens. (
  • In children, acute lymphoblastic leukemia and brain tumors are most common, except in Africa, where non-Hodgkin lymphoma occurs more often. (
  • Characterize the potential of the molecular markers within circulating tumor cells as markers of response (e.g. (
  • Recent years, circulating tumor cells (CTCs), which detached from the primary tumor and intravasated into the blood, became the research hotspot. (
  • PURPOSE: This phase I/II trial is studying the side effects and best dose of crizotinib and to see how well it works in treating young patients with relapsed or refractory solid tumors or anaplastic large cell lymphoma. (
  • To estimate the maximum-tolerated dose and recommended phase II dose of crizotinib administered orally twice daily to children with relapsed or refractory solid tumors or anaplastic large cell lymphoma (ALCL). (
  • PURPOSE: This phase I trial is studying the side effects and best dose of irinotecan when given together with temozolomide and vincristine in treating young patients with refractory solid tumors. (
  • Determine the maximum tolerated dose and recommended phase II dose of irinotecan when administered with temozolomide and vincristine in young patients with refractory solid tumors, including brain tumors. (
  • ELIGIBILITY CRITERIA FOR ENROLLMENT ONTO APEC1621SC: Patients with recurrent or refractory solid tumors (including non-Hodgkin lymphomas, histiocytoses [e.g. (
  • PURPOSE: The investigators will conduct a phase 1 trial of Selinexor in children with recurrent or refractory solid tumors, including CNS tumors using the Rolling Six design. (
  • PURPOSE: The main purpose of this study is to evaluate the safety of the study drug known as ramucirumab in children with recurrent or refractory solid tumors including central nervous system (CNS) tumors. (
  • PURPOSE: This is a 2-part study of pembrolizumab (MK-3475) in pediatric participants who have either advanced melanoma or a programmed cell death ligand 1 (PD-L1)-positive advanced, relapsed or refractory solid tumor or lymphoma. (
  • encompassing advanced solid tumors and relapsed or refractory T-ALL/LBL). (
  • We observed durable cancer shrinkages in some patients with platinum-resistant small-cell tumors that are typically fatal within weeks of recurrence. (
  • As Dr. Thomas noted, durable tumor regressions were observed in patients with platinum-resistant SCNCs, typically fatal within weeks of recurrence. (
  • Four patients, all with solid tumors that initially were subtotally resected, had evidence of tumor recurrence. (
  • Description: Patients with solid tumor or brain tumor in the 1-18 years old stratum. (
  • As a member of the North American Brain Tumor Coalition, we offer qualified patients access to several clinical trials sponsored by the National Cancer Institute. (
  • While most types of primary brain cancer may spread within the brain, it is rare for a primary brain tumor to spread outside the brain. (
  • For the solid tumor expansion cohorts, enrollment is limited to the following solid tumors: melanoma and renal cell carcinoma. (
  • In sporadic clear cell renal cell carcinoma (CCRCC), the von Hippel Lindau (VHL) gene is inactivated by mutation or methylation in the majority of primary (P) tumors. (
  • Note also that patients with prostate cancer, lung cancer, and renal cell carcinoma had the highest risk of fatal adverse events. (
  • Patients with prostate cancer had the highest risk of fatal adverse events (RR 3.85 versus control), followed by lung cancer (RR 2.12) and renal cell carcinoma (RR 1.11). (
  • Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas. (
  • I. To evaluate the prognostic and predictive value of MET mutations, MET copy number or other markers of MET signaling in patients with mPRCC treated with putative MET inhibitors. (
  • Mutations in the von Hippel Lindau ( VHL ) tumor suppressor gene are associated with hereditary and sporadic forms of clear cell renal carcinoma only. (
  • While the overall response rate (ORR) to VEGF-targeted therapy in patients with metastatic RCC was not correlated with VHL inactivation, subset analysis suggested that loss of function VHL mutations may identify patients with increased ORR to VEGF-targeted agents. (
  • The PARP inhibitor talazoparib produces cytotoxicity in human cancer cell lines and animal models of tumors that harbor mutations that compromise DNA repair pathways. (
  • In this study, single agent talazoparib (1000 µg/day) was administered to patients with deleterious BRCA1 or BRCA2 mutations and advanced solid tumors in 28 day cycles. (
  • Virtually every patient had an increased number of mutations in their metastatic tumors, according to a press release. (
  • That finding led Chinnaiyan to suggest that when inherited mutations are found in people with metastatic solid tumors, family members should consider whether to seek out genetic testing and counseling to assess their cancer risks. (
  • Preliminary findings suggest that 75% have "actionable mutations," meaning there are already treatments on the market that target the abnormalities in their metastatic tumors. (
  • Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. (
  • Empliciti is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. (
  • Fresh specimens from acute myeloid leukemia (AML) and multiple myeloma (MM) patients and normal peripheral blood mononuclear cells (PBMCs) and bone marrow mononuclear cells (BMMCs) from nondiseased donors were acquired from AllCells (Emeryville, CA, USA). (
  • combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. (
  • Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma. (
  • PRINCETON, N.J.--( BUSINESS WIRE )-- Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Empliciti (elotuzumab) injection for intravenous use in combination with pomalidomide and dexamethasone (EPd) for the treatment of adult patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor. (
  • Despite remarkable recent innovations with novel therapies for the treatment of multiple myeloma, many patients still face poor outcomes, and particularly in the relapsed and relapsed, refractory setting," 5 said Paul Richardson, M.D., clinical program leader and director of clinical research of the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute. (
  • Relapse can be overwhelming and extremely challenging for multiple myeloma patients, particularly after they have already tried several therapies," 10 said Paul Giusti, president and chief executive officer of the Multiple Myeloma Research Foundation. (
  • ELOQUENT-3 was a randomized, open-label Phase 2 study evaluating the addition of Empliciti to pomalidomide and dexamethasone versus pomalidomide and dexamethasone in 117 patients with multiple myeloma who received two or more prior therapies and were either refractory or relapsed and refractory to lenalidomide and a proteasome inhibitor. (
  • Celyad expects to enroll 14 patients per cancer type, including acute myeloid leukemia and multiple myeloma. (
  • Celyad's first Phase I clinical trial of their CAR-T candidate was tested in patients with acute myeloid leukemia and multiple myeloma. (
  • Recombinant interleukin-12 may kill tumor cells by blocking blood flow to the tumor and by stimulating white blood cells to kill tumor cells. (
  • RATIONALE: S-3304 may stop or slow the growth of solid tumors by stopping blood flow to the tumor. (
  • RATIONALE: GW786034 may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth and by stopping blood flow to the tumor. (
  • They were large (mean size of resected tumor was 8.4 cm), benign, had solid and cystic areas, and were evenly distributed in the pancreas. (
  • Even when brain tumors are benign (not cancer), they can cause serious problems. (
  • Oncocytoma is the most common benign solid renal tumor and constitute 3-7% of all primary renal neoplasms. (
  • These contrast with benign tumors, which do not spread. (
  • Incidence estimates and associated 95% confidence intervals (CI) are provided for up to 10 years of follow-up for all tumor types combined and stratified by tumor type and stage at diagnosis. (
  • This phase II trial studies how well prexasertib works in treating patients with advanced solid tumors exhibiting replicative stress or homologous recombination repair deficiency. (
  • To utilize clinical and biological data to screen for eligibility to phase 2 pathway-targeting specific subprotocols of pathway-targeting agents in pediatric patients with advanced solid tumors, non-Hodgkin lymphomas, and histiocytic disorders. (
  • This phase II trial studies how well sorafenib tosylate works in treating younger patients with relapsed or refractory rhabdomyosarcoma, Wilms tumor, liver cancer, or thyroid cancer. (
  • PURPOSE: Phase I trial to study the effectiveness of S-3304 in treating patients who hav. (
  • Phase I: Patients will be accrued, in an alternating fashion, to 1 of 2 treatment groups. (
  • Phase II: Patients receive pemetrexed disodium bortezomib (at the MTD) as in either group I or group II of the phase I portion of the study. (
  • After completion of study treatment, patients in phase I are followed for 30 days and patients in phase II are followed periodically. (
  • Determine the recommended phase II dose of this drug in these patients. (
  • PURPOSE: This is a phase 1 study to evaluate the safety of intralesional talimogene laherparepvec administration in pediatric subjects with advanced non-CNS tumors that are amenable to direct injection. (
  • ADVL1414: A Phase 1 Study of Selinexor (KPT-330, IND#125052), a Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors. (
  • PURPOSE: This phase I trial studies the side effects and best dose of prexasertib in treating pediatric patients with solid tumors that have come back after a period of time during which the tumor could not be detected or does not respond to treatment. (
  • PURPOSE: This phase II trial studies how well cabozantinib-s-malate works in treating younger patients with sarcomas, Wilms tumor, or other rare tumors that have come back, do not respond to therapy, or are newly diagnosed. (
  • PURPOSE: Phase I trial to study the effectiveness of amifostine in protecting from the side effects of peripheral stem cell transplantation in treating patients who have high-risk or relapsed solid tumors. (
  • Tumor must be recurrent or treatment refractory with no remaining alternative, approved therapy options, with the following exception: melanoma patients enrolled in the expansion phase must have previously received ipilimumab and, for patients with the BRAF V600E mutation, vemurafenib, or have been offered such therapies and refused, and patients must have progressive disease subsequent to previous therapies. (
  • Randomized phase II trial of hypofractionated dose-escalated photon IMRT or proton beam therapy versus conventional photon irradiation with concomitant and adjuvant temozolomide in patients with newly diagnosed glioblastoma. (
  • A phase II randomized trial of proton vs. photon therapy (IMRT) for cognitive preservation in patients with IDH mutant, low to intermediate grade gliomas. (
  • A double-blind, placebo-controlled, randomized phase III study of ipatasertib in combination with paclitaxel as a treatment for patients with PIK3CA/AKT1/PTEN-altered, locally advanced or metastatic, triple-negative breast cancer or hormone receptor- positive, HER2-negative breast cancer. (
  • Jhaveri and colleagues conducted an open-label phase 1 study to assess taselisib for patients with PIK3CA -mutated tumors who did not respond to or progressed after at least one prior treatment. (
  • NEW YORK (Reuters Health) - Combining an ataxia telangiectasia and rad3-related (ATR) inhibitor with topoisomerase 1 (TOP1) yielded an objective response in more than a third of patients with small-cell lung cancer (SCLC) in a phase-2 proof-of-concept trial. (
  • Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL. (
  • Our lead candidate, seribantumab, inhibits tumor growth driven by NRG1 fusions and is currently being clinically tested in the Phase 2 CRESTONE study for patients with tumors of any origin that have an NRG1 fusion. (
  • In addition to extensive nonclinical characterization and testing, seribantumab has been administered to 847 patients across 12 Phase 1 and 2 studies, both as a monotherapy and in combination with various anticancer therapies. (
  • CRESTONE is a Phase 2 tumor-agnostic 'basket trial' of seribantumab in patients with any solid tumor that harbor an NRG1 fusion. (
  • We are pleased to see the publication in Cancer Discovery of these Phase 1 data, which build upon our previously reported 79% response rate in 24 patients with TRK, ROS1, or ALK-driven extracranial solid tumors. (
  • The longest duration of clinical benefit in patients with fusions observed in the Phase 1 setting was a patient with ROS1-rearranged lung cancer remaining on therapy in confirmed response at 32.2 months as of the data cutoff. (
  • In the Phase 2 LEAP-004 trial, KEYTRUDA plus LENVIMA showed an objective response rate (ORR) of 21.4% (95% CI: 13.9-30.5) in patients with unresectable or advanced melanoma who had previously progressed on an anti-PD-1/PD-L1 therapy. (
  • LEAP-004 ( , NCT03776136 ) is a Phase 2, single-arm, open-label trial evaluating KEYTRUDA in combination with LENVIMA in patients with unresectable or advanced melanoma who had progressed on an anti-PD-1/PD-L1 therapy within 12 weeks. (
  • The companies also plan to evaluate tisotumab vedotin in multiple solid tumors in a phase 2 trial this year. (
  • This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. (
  • The highest incidence of fatal events in bevacizumab patients was 13.4% and occurred in a phase II trial involving patients with non-small cell lung cancer (NSCLC). (
  • We describe the multiple-phase multidetector computed tomography (CT) findings of SPTP in a 24-year-old woman who had 2 separate tumors in the head and in the tail of the pancreas, which will add evidence for accurate diagnosis and management. (
  • This is a multicenter, open-label, Phase 1 study in pediatric patients with advanced solid or primary CnS tumors. (
  • Some tumors maybe difficult to identify either because they are too small and/or they are only visible during a particular phase at dynamic contrast-series, or at MRI. (
  • A combination of the experimental histone deacetylase (HDAC) inhibitor entinostat with the programmed cell death protein 1 (PD-1) inhibitor pembrolizumab showed clinical responses in patients with melanoma that had progressed on prior anti-PD-1 treatment, according to results from the phase. (
  • ROCKVILLE, Md., Feb. 23, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), today announced that is has begun enrolling patients into a Phase IIa clinical study of Supinoxin™ in metastatic triple negative breast cancer (TNBC). (
  • The dosing of the first patient in the Phase IIa clinical trial with Supinoxin™ is a major milestone for the program," said Peter D. Suzdak, Ph.D., Chief Executive Officer of Rexahn. (
  • THOUSAND OAKS, Calif. , Jan. 28, 2021 /PRNewswire/ -- Amgen ( AMGN ) - Get Report today announced results from the Phase 2 cohort of the CodeBreaK 100 clinical study evaluating investigational sotorasib (AMG 510) in 126 patients with KRAS G12C -mutated advanced non-small cell lung cancer (NSCLC). (
  • In an effort to apply CAR-T immunotherapy to treat solid tumors, biotech company Celyad has started to enroll patients in its Phase Ib THINK clinical trial . (
  • After completion of study treatment, patients are followed for 1 month and then annually thereafter. (
  • Participants enrolling to the HR or replicative stress cohorts during stage 1 must have disease that is amenable to biopsy and be willing to undergo a pre-treatment tumor biopsy. (
  • After completion of study treatment, patients are followed up periodically. (
  • After completion of study treatment, patients are followed up for 3 years. (
  • The B-Cell Lymphoma Moon Shot is revolutionizing the conventional medical research approach to rapidly translate findings into patient treatment options and develop personalized therapeutic strategies. (
  • 2) Patients with acute T-ALL/LBL that are refractory/resistant to current treatment options or for which no standard therapy is available. (
  • no patients had grade ≥ 3 treatment-related TEAEs. (
  • treatment-related grade 3 TEAEs occurred in two patients with HCC. (
  • Determine the maximum tolerated dose (MTD) of bortezomib when administered with pemetrexed disodium in 2 different treatment schedules in these patients. (
  • Up to 12 patients receive treatment at the MTD. (
  • These aggressive approaches show promise for improving the treatment of many types of brain tumors . (
  • OUTLINE: Patients are randomized to 1 of 4 treatment arms. (
  • Children's Minnesota provides care for the majority of children diagnosed with solid tumors and rare tumors in the state of Minnesota and are the trusted regional treatment center for many children in North Dakota, South Dakota, Iowa and Wisconsin. (
  • Special expertise in treatment of rare tumors. (
  • Treatment of children and adolescents diagnosed with a rare tumor is individualized utilizing the expertise of our specialists in addition to consultation with other experts from around the world. (
  • Grade ≥3 treatment-related adverse events occurred in 4 patients (skin infection secondary to localized bullous pemphigoid, asymptomatic lipase increase, colitis with associated anemia, and gastroparesis with hypokalemia). (
  • ReRT was a reasonable treatment option for patients with locoregionally recurrent rectal cancer. (
  • However, despite advances in treatment modalities, local recurrences still occur in 5-15% of patients, and the majority of locoregional recurrences occur within the initial RT field ( 5 , 6 ). (
  • Mandatory paired tumor biopsies were obtained pre-treatment and 3-6 hrs post-treatment on cycle 1 day 8. (
  • In summary, talazoparib demonstrated significant clinical activity as a single agent in patients with BRCA-deficient tumors and produced substantial reductions in tumor PAR levels in matched pre and post-treatment tumor biopsies. (
  • Di S, Li Z. Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects. (
  • Together with our peers we work towards a future in which each unique test result can be matched with a purpose-built precision medicine to enable an individualized treatment plan for each patient. (
  • CRESTONE offers a clinical trial opportunity for patients with advanced solid tumors who have not responded or are no longer responding to treatment. (
  • Bayer HealthCare and Onyx Pharmaceuticals, Inc., an Amgen subsidiary (Nasdaq: AMGN), today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application for the oral multi-kinase inhibitor NEXAVAR ® (sorafenib) tablets for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) refractory to radioactive iodine treatment. (
  • NEXAVAR is the first and only FDA-approved therapy for this type of thyroid cancer and is a positive development for patients who previously had limited treatment options. (
  • We are pleased to be able to offer NEXAVAR as a treatment option for patients with thyroid cancer who are no longer responding to standard therapy,' said Pablo J. Cagnoni, M.D., President, Onyx Pharmaceuticals, Inc. 'We are committed to making this treatment available to physicians and their patients as quickly as possible. (
  • An unmet medical need exists for this type of thyroid cancer, underscoring the need for new therapies,' said Gary Bloom, Executive Director of ThyCa: Thyroid Cancer Survivors' Association, Inc. 'We are excited that an FDA-approved treatment is now available to patients coping with this challenging type of thyroid cancer. (
  • Physicians now have an approved treatment option that may help improve care in this patient population. (
  • A total of 417 patients with locally recurrent or metastatic, progressive differentiated thyroid carcinoma refractory to radioactive iodine treatment were randomized to receive 400 mg of oral sorafenib twice daily (207 patients) or matching placebo (210 patients). (
  • Drug-related adverse reactions that resulted in treatment discontinuation were reported in 14% of NEXAVAR-treated patients compared to 1.4% of placebo-treated patients. (
  • Age, stage, and biological features encountered in tumor cells are important prognostic factors and are used for risk stratification and treatment assignment. (
  • Determinations of DPC4 status at initial diagnosis may be of value in stratifying patients into treatment regimens related to local control versus systemic therapy. (
  • Grade 3-4 treatment-related adverse events (TRAEs) occurred in 32% of patients receiving the Opdivo plus Yervoy combination. (
  • In addition, we plan to evaluate tisotumab vedotin in collaboration with Genmab in other solid tumors where there remains an unmet medical need for new treatment options. (
  • The data from CLARINET ® is considered investigational, as Somatuline ® is not indicated for anti-proliferative treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in any market. (
  • Part 1 (Dose Escalation) Histologically confirmed diagnosis of a locally advanced or metastatic solid tumor for which carboplatin is considered appropriate treatment. (
  • 1 Discontinuation of any component of the treatment regimen due to adverse reactions occurred in 5.0% of patients in the EPd arm, compared to 1.8% of patients in the control arm. (
  • Patient with unresectable locally advanced or metastatic melanoma who has received no prior treatment or progressed on or after prior systemic therapy. (
  • Thirty-four patients received treatment. (
  • It is important for physicians and patients to recognize the risks as well as the benefits associated with bevacizumab treatment and to monitor closely to identify and treat serious adverse effects. (
  • Analysis of fatal events by tumor type showed significant variation ( P =0.001), suggesting that tumor type or associated treatment might have a major influence on the risk of fatal adverse events, the authors wrote. (
  • Based on follow-up analysis of the 11 patients, recommendations are proposed for the treatment of primary cerebral neuroblastomas. (
  • Also, our aim is to improve staging and evaluation of tumor response to treatment. (
  • Principles of the so-called "precision medicine" (i.e., the right patient is provided with the right treatment at the right time) play a central role. (
  • CT-based analysis of tumors' morphometric structure may improve our ability to identify which patients have aggressive tumors and who will have a good response to treatment. (
  • This is a study of a drug called PSB205 for the treatment of solid tumors. (
  • Clinical outcomes were assessed and stratified by tumor location and type of treatment. (
  • The study showed preliminary evidence of clinical activity with seven patients experiencing disease stabilization and three patients continuing treatment beyond one year. (
  • Patients with advanced non-small cell lung cancer who have failed first-line treatment face extremely poor outcomes with limited treatment options available to them, and Amgen has been committed to changing that,' said David M. Reese , M.D., executive vice president of Research and Development at Amgen. (
  • TRAEs led to treatment discontinuation in only 7.1% of patients. (
  • These are patients who have progressive disease after standard treatment, so they need additional treatments, and the fact that we are seeing rapid tumor shrinkages and durable responses in these patients, is for me a step forward and a win for patients. (
  • Currently there are no targeted treatment options for them, and I am excited about the advances that Amgen is pioneering in this field to potentially help improve patient outcomes,' said Dr. Upal Basu Roy , vice president of Research, LUNGevity. (
  • Expert-reviewed information summary about the treatment of childhood salivary gland tumors. (
  • This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of childhood salivary gland tumors. (
  • Cancer genomic heterogeneity thereby results in varying degrees of clinical presentation and tumor biology, which impedes treatment options and poses a significant challenge to cancer management. (
  • These signatures have also been shown to be useful as diagnostic or prognostic tools to discriminate patients with greater homogeneity, assist in molecular re-staging, predict outcome or guide treatment, and to identify clinically relevant therapeutic targets. (
  • We do believe that the THINK study, which is the first to use multiple dosing in patients suffering from very aggressive solid or hematologic metastatic tumors, potentially opens a new avenue for cancer treatment. (
  • 1) Patients with advanced solid tumor malignancy (with measurable disease as per Recist for patients enrolled in the expansion cohort) that is resistant to standard therapy or for which no standard therapy is available. (
  • Entrectinib remains the only TRK inhibitor to have published data demonstrating RECIST responses in NSCLC and in patients with cancer in the CNS. (
  • Today, the majority of clinical trials evaluating cancer treatments for objective response in solid tumors use RECIST. (
  • The Pancreas TumorMACS™ Medium has been developed for derivation and expansion of human tumor cell cultures from pancreatic tumors. (
  • The main differential diagnosis was pancreatic endocrine tumor. (
  • Patients with less than or equal to 25% lymphoblasts in the bone marrow either at initial diagnosis or at study entry are considered to have T-ALL. (
  • SCLC is a recalcitrant cancer, with most patients dying within a year of their diagnosis," Dr. Anish Thomas of the National Cancer Institute in Bethesda told Reuters Health by email. (
  • Each patient's index date was set to the date of his or her first solid tumor diagnosis in the selection period. (
  • Thus, 80% of patients with pancreatic cancer have advanced stage disease at diagnosis and are not candidates for surgical intervention. (
  • As Head of the Liver Carcinogenesis Section, Dr. Wang oversees a basic/translational research program emphasizing new molecular approaches to define tumor subtypes and identify biomarkers for early detection, diagnosis, prognosis and prediction, to delineate the molecular mechanisms of liver cancer with applications towards precision medicine. (
  • We are exploring molecular mechanisms related to primary liver cancer to learn how cancer cells initiate and metastasize, and to identify biomarkers useful for early diagnosis and molecular targets for effective therapy. (
  • As expected, when the VHL gene was mutated in both the P tumor and M lesion, the mutation was identical. (
  • The Michigan team also compared tumor DNA to normal DNA, which led them to a surprising discovery: 12% of the patients with metastatic tumors had an inherited mutation. (
  • Investigator-assessed responses were observed irrespective of tumor BRAF or KRAS mutation status, tumor PD-L1 expression or clinical history of Lynch syndrome. (
  • Patients must meet the criteria below and have received results from one of the designated outside laboratories indicating a "rare variant" that is an actionable Mutation of Interest (aMOI) for specific select subprotocols. (
  • These results are encouraging and clinically meaningful for patients with advanced NSCLC harboring the KRAS G12C mutation,' said Bob T. Li , MD, PhD, MPH, medical oncologist and principal investigator at Memorial Sloan Kettering Cancer Center. (
  • In exploratory analyses, encouraging tumor response to sotorasib was observed across a range of biomarker subgroups, including patients with negative or low PD-L1 expression level and those with STK11 mutation. (
  • The aim of this study was to determine the feasibility of using activity trackers (AT) to assess the patient prognosis and the effects of palliative RT. (
  • Patients with low-risk and intermediate-risk neuroblastoma have excellent prognosis and outcome. (
  • For children diagnosed with metastatic or recurrent solid tumors, for which the utility of external-beam radiotherapy is limited, the prognosis is particularly poor. (
  • Most children diagnosed with primary disseminated or recurrent pediatric solid tumors such as neuroblastoma, rhabdomyosarcoma, or Ewing sarcoma have a particularly poor prognosis, despite the availability of highly toxic multimodality therapies ( 3 ). (
  • In a study reported in the Journal of the National Cancer Institute, Dessinioti et al found that thin nodular primary melanomas are associated with aggressive characteristics that may portend poorer prognosis vs superficial spreading melanomas. (
  • Objective: To study the outcomes of solid tumors of the colon and rectum in pediatric patients. (
  • Thus, elucidation of factors leading to a second cancer and methods to avoid it may have substantial impact on both individual patient outcomes and public health. (
  • Statistically significant and clinically meaningful improvements were observed in key patient reported outcomes, including symptoms, functioning and quality of life. (
  • The availability of tumor-targeting radiopharmaceuticals for molecular radiotherapy (MRT) has demonstrated improved outcomes in these patient populations, but options are nonexistent or limited for most pediatric solid tumors. (
  • The primary aims of this study were to describe the clinical and microbiologicalcharacteristics and outcomes in critically ill cancer patients with severe pneumonia. (
  • More favorable outcomes were observed in LCC patients, but not in RCC patients, treated with anti-EGFR agents compared with those who received Bevacizumab. (
  • We conduct research to improve transplant outcomes provide support and resources for patients, and partner with a global network. (
  • Here we describe the proteomic identification of the novel cell surface antigen SAIL (Surface Antigen In Leukemia) and the preclinical characterization of ADCs with potent in vitro and in vivo activity against SAIL-expressing hematologic tumors. (
  • We investigated the clinicopathologic data, immunohistochemical expression of the pan-endocrine markers, hormones, steroid receptors, and p53 overexpression in pancreatic SCPTs from eight Chinese patients (seven women, one man) collected over a 24-year period. (
  • A study looking at targeted therapy according to tumor markers for people with meningiomas. (
  • Although of great interest, the markers that predict activity of this combination will need to be confirmed in a prospective study before they can be used to select patients," concluded Dr. Giaccone, who was not involved in the study. (
  • There are currently no known tumor markers that can be used to screen for and detect early pancreatic neoplasia. (
  • Kong Y, Lyu N, Wu J, Tang H, Xie X, Yang L, Li X, Wei W, Xie X. Breast cancer stem cell markers CD44 and ALDH1A1 in serum: distribution and prognostic value in patients with primary breast cancer. (
  • Her laboratory examinations including serum tumor markers serum carcinoembryonic antigen, CA 19-9 were within normal limits. (
  • Cohorts of 3-6 patients receive escalating doses of irinotecan until the maximum tolerated dose (MTD) is determined. (
  • I. To determine the maximum-tolerated dose of entinostat in combination with sorafenib tosylate in patients with advanced, inoperable, or metastatic solid tumors. (
  • Cohorts of 3-6 patients per group receive escalating doses of bortezomib until the maximum tolerated dose (MTD) is determined. (
  • Determine the dose-limiting toxicity and maximum tolerated dose of tumor vasculature-targeted tumor necrosis factor alpha (NGR-TNF) in patients with advanced solid tumors. (
  • Cohorts of 3-6 patients receive escalating doses of amifostine until the maximum tolerated dose is determined. (
  • We show that in orthotopic models of syngeneic murine triple-negative breast cancer (EMT6), CTX administered at 140 mg/kg every 6 days (CTX140 1q6d) is superior at inhibiting primary tumor growth when compared to maximum tolerated dose or daily oral (continuous) low-dose CTX. (
  • Two ongoing clinical trials are investigating the combination in a larger patient population, he added. (
  • Get details about our clinical trials that are currently enrolling patients. (
  • In addition, these studies emphasize the utility of basket clinical trials that focus on molecular selection, independent of tumor histology, particularly in NTRK gene fusions, which are detected across multiple cancer types. (
  • Lapatinib may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. (
  • Cabozantinib s-malate, crizotinib, savolitinib, and sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. (
  • Olaparib and onalespib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. (
  • South Korean MPN patients had a significantly higher risk of developing second primary solid tumors than that of the general population. (
  • Patients who did not experience severe late toxicity events showed a significantly higher number of recurred tumors at the posterior or lateral location compared to axial or anterior location. (
  • Furthermore, Anxa3 knockdown significantly decreased MMP-2 and N-cadherin expression and increased E-cadherin expression both in cell lines in vitro and in tumor nodules examined during in vivo tumorigenesis assays. (
  • In the overall study population, OS was not significantly different for patients treated with Cetuximab or Panitumumab as compared to those receiving Bevacizumab. (
  • Supinoxin™ has been shown to significantly inhibit tumor growth in a preclinical xenograft model of triple negative breast cancer. (
  • BRIEF SUMMARY: This study is designed to investigate whether the use of copanlisib is safe, feasible and beneficial to pediatric patients with solid solid tumors or lymphoma that are recurrent or refractory to standard therapy. (
  • Patients with a higher tumor burden had a higher clearance of bevacizumab compared with patients who had a tumor burden below the median. (
  • Severe late toxicity events occurred in 17 patients, and the median time from reRT to severe late toxicity event was 10.5 months (range 2.3-33.3 months). (
  • Median TSD in primary tumors was 0.57. (
  • Among 13 patients with ROS1 -rearranged NSCLC, the median duration of response was 17.3 months. (
  • Median OS was 13.9 months (range: 10.8-not reached [NR]), with death occurring in 44.7% of patients, and the nine-month OS rate was 65.4% (95% CI: 55.2-73.8). (
  • The Opdivo plus Yervoy combination cohort included 119 patients with a median follow-up of 13.4 months. (
  • 21 of 30 patients) and median PFS was 20.0 months (95% CI: 10.1-not reached). (
  • CD74-ROS1-positive patients had a trend towards a higher ORR and longer median PFS. (
  • The presence and prognostic significance of tumor stroma at primary and metastatic sites were evaluated. (
  • We aimed to measure CD44 and ALDH1A1 (major contributor to ALDH1 activity) levels in serum and explore the prognostic value in primary breast cancer patients. (
  • Serum CD44 was an independent prognostic indicator in primary breast cancer. (
  • Emerging evidence supports a prognostic role of primary tumor location in metastatic colon cancer (mCC). (
  • Neuroblastoma is the most common extracranial solid tumor of infancy. (
  • The patterns of distribution of these cells correlates with the sites of primary neuroblastoma presentation. (
  • The differences in outcome for patients with neuroblastoma are striking. (
  • Over the last 2 decades, many chromosomal and molecular abnormalities have been identified in patients with neuroblastoma. (
  • In this study, we evaluated the in vivo pharmacokinetics of 124 I-CLR1404 (CLR 124) and estimated theranostic dosimetry for 131 I-CLR1404 (CLR 131) MRT in murine xenograft models of the pediatric solid tumors neuroblastoma, rhabdomyosarcoma, and Ewing sarcoma. (
  • Primary cerebral neuroblastoma is a distinct pathological and clinical entity that differs from other primitive neuroectodermal tumors. (
  • After rhabdomyosarcoma, they are the most common tumor in the head and neck. (
  • F) Prevalence of intraluminal debris in 4-week tumors quantified as a percentage of total tumor area (intact epithelium + debris). (
  • Tumor stroma density (TSD) was quantified as tumor stroma per total tumor area. (
  • Conduct exploratory translational laboratory correlative studies utilizing banked biospecimens (tumor and blood) obtained at baseline and during therapy. (
  • TSD should be used as an objective, quantitative assessment of tumor stroma in correlative and therapeutic trials of pancreatic cancer. (
  • Subject-specific tumor dosimetry for CLR 131 MRT presents a correlative relationship with tumor-growth delay after CLR 131 MRT. (
  • Determine the safety, including dose-limiting toxicities, and feasibility of combining bortezomib with pemetrexed disodium in patients with advanced non-small cell lung cancer (NSCLC) or other solid tumors. (
  • ROS1 rearrangements are found in 1% of lung cancer patients. (
  • Key eligibility criteria included patients who were 18 years of age or older with advanced/metastatic lung cancer and centrally confirmed ROS1-rearranged lung cancer (fluorescence-in situ hybridization). (
  • Neutrophils Oppose Uterine Epithelial Carcinogenesis via Debridement of Hypoxic Tumor Cells. (
  • Epithelial salivary gland tumors of children and adolescents in west China population: a clinicopathologic study of 79 cases. (
  • Lapatinib may help paclitaxel work better by making tumor cells more sensitive to the drug. (
  • Giving lapatinib together with paclitaxel may kill more tumor cells. (
  • Radiolabeled monoclonal antibodies, such as iodine I 131 monoclonal antibody 8H9, can find tumor cells and carry tumor-killing substances to them without harming normal cells. (
  • Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. (
  • Genetic tests look at the unique genetic material (genes) of patients' tumor cells. (
  • Np95/Uhrf1 regulates tumor suppressor gene expression of neural stem/precursor cells, contributing to neurogenesis in the adult mouse brain. (
  • A solid, unencapsulated tumor of the KIDNEY composed of spindle mesenchymal cells that resemble FIBROBLASTS or muscle cells. (
  • The workflow enables highly standardized cell line derivation and still offers the opportunity to seed dissociated tumors and/or selected cell fractions such as isolated tumor cells or tumor subpopulations. (
  • The presence of red blood cells (RBCs) hampers the accurate determination of cell viability as well as absolute cell counts for tumor-infiltrating leukocytes, cancer stem cells, and other tumor-resident cells. (
  • Low-dose daily metronomic cyclophosphamide (LDM CTX) has been shown to reduce numbers of regulatory T cells (T regs ) preclinically and in patients 9 , 10 . (
  • Inhibition of poly (ADP-ribose) polymerase (PARP) sensitizes tumor cells to DNA damage that would normally be repaired through the base excision repair pathway. (
  • Theoretically, CAR-T cells can specifically localize and eliminate tumor cells by interacting with the tumor-associated antigens (TAAs) expressing on tumor cell surface. (
  • Current studies demonstrated that various TAAs could act as target antigens for CAR-T cells, for instance, the type III variant epidermal growth factor receptor (EGFRvIII) was considered as an ideal target for its aberrant expression on the cell surface of several tumor types. (
  • Chmielewski M, Hombach AA, Abken H. Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma. (
  • Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR chain. (
  • Animal tests indicate that about 0.01% of circulating cancer cells from solid tumors establish successful metastatic colonies (Fidler, 1993). (
  • Almost all tumor cells have shortened telomeres, which are maintained at a constant length (Allshire et al. (
  • While SAIL is widely expressed in CLL, AML, MM, DLBCL and FL patient samples, expression in cancer cell lines is mostly limited to cells of AML origin. (
  • Examining RNA allowed the team to zero in on immune cells surrounding the tumors, which could eventually lead to clues about who is most likely to respond to immunotherapy, Chinnaiyan said. (
  • ARL4C ASO accumulated in cancer cells more efficiently than the surrounding normal cells in the liver and decreased ARL4C expression in the tumor. (
  • Both inter-tumor and intra-tumor heterogeneity have been recognized, possibly emanating from the presence of cancer stem cells or selection by clonal evolution. (
  • The THINK trial is a world first, evaluating CAR-T NKR-2 cells in both hematological and solid tumors. (
  • A neoplasm or tumor is a group of cells that have undergone unregulated growth and will often form a mass or lump, but may be distributed diffusely. (
  • All tumor cells show the six hallmarks of cancer. (
  • Because we diagnose over 200 children and adolescents with cancer annually, we are among the top 10 largest pediatric cancer centers in the nation and therefore diagnose children and teens with rare pediatric tumors. (
  • The article titled "Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors" is available online at and has been published in the July 17th edition (N. Engl. (